

Please cite the Published Version

Fountoulakis, Konstantinos N, Karakatsoulis, Gregory, Abraham, Seri, Adorjan, Kristina, Ahmed, Helal Uddin, Alarcón, Renato D, Arai, Kiyomi, Auwal, Sani Salihu, Berk, Michael, Levaj, Sarah, Bobes, Julio, Bobes-Bascaran, Teresa, Bourgin-Duchesnay, Julie, Bredicean, Cristina Ana, Bukelskis, Laurynas, Burkadze, Akaki, Abud, Indira Indiana Cabrera, Castilla-Puentes, Ruby, Cetkovich, Marcelo, Colon-Rivera, Hector, Corral, Ricardo, Cortez-Vergara, Carla, Crepin, Piirika, De Berardis, Domenico, Delgado, Sergio Zamora, De Lucena, David, De Sousa, Avinash, Stefano, Ramona Di, Dodd, Seetal, Elek, Livia Priyanka, Elissa, Anna, Erdelyi-Hamza, Berta, Erzin, Gamze, Etchevers, Martin J, Falkai, Peter, Farcas, Adriana, Fedotov, Ilya, Filatova, Viktoriia, Fountoulakis, Nikolaos K, Frankova, Iryna, Franza, Francesco, Frias, Pedro, Galako, Tatiana, Garay, Cristian J, Garcia-Álvarez, Leticia, García-Portilla, Maria Paz, Gonda, Xenia, Gondek, Tomasz M, González, Daniela Morera, Gould, Hilary, Grandinetti, Paolo, Grau, Arturo, Groudeva, Violeta, Hagin, Michal, Harada, Takayuki, Hasan, Tasdik M, Razali, Salmi, Hilbig, Jan, Hossain, Sahadat, Iakimova, Rossitza, Ibrahim, Mona, Iftene, Felicia, Ignatenko, Yulia, Irrarazaval, Matias, Ismail, Zaliha, Ismayilova, Jamila, Jakobs, Asaf, Jakovljević, Miro, Jakšić, Nenad, Javed, Afzal, Kafali, Helin Yilmaz, Karia, Sagar, Kazakova, Olga, Khalifa, Doaa, Khaustova, Olena, Koh, Steve, Kopishinskaia, Svetlana, Kosenko, Korneliia, Vadon, Nikolett Beata, Lalljee, Alisha, Liewig, Justine, Majid, Abdul, Malashonkova, Evgeniia, Malik, Khamelia, Malik, Najma Iqbal, Mammadzada, Gulay, Mandalia, Bilvesh, Marazziti, Donatella, Marčinko, Darko, Martinez, Stephanie, Matiekus, Eimantas, Mejia, Gabriela, Memon, Roha Saeed, Martínez, Xarah Elenne Meza, Mickevičiūtė, Dalia, Milev, Roumen, Mohammed, Muftau, Molina-López, Alejandro, Morozov, Petr, Muhammad, Nuru Suleiman, Mustač, Filip, Naor, Mika S, Nassieb, Amira, Navickas, Alvydas, Okasha, Tarek, Pandova, Milena, Panfil, Anca-Livia, Panteleeva, Liliya, Papava, Ion, Pavlichenko, Alexey, Pejuskovic, Bojana, da Costa, Mariana Pinto, Popkov, Mikhail, Popovic, Dina, Raduan, Nor Jannah Nasution, Ramírez, Francisca Vargas, Rancans, Elmars, Hashim, Nurul Azreen, Rebok, Federico, Rewekant, Anna, Flores, Elena Ninoska Reyes, Rivera-Encinas, María Teresa, Saiz, Pilar, de Carmona, Manuel Sánchez, Martínez, David Saucedo, Saw, Jo Anne, Saygili, Gökem, Schneidereit, Patricia, Shah, Bhumiika, Shirasaka, Tomohiro, Silagadze, Ketevan, Sitanggang, Satti, Skugarevsky, Oleg, Spikina, Anna, Mahalingappa, Sridevi Sira, Stoyanova, Maria, Szczegielniak, Anna, Tamasan, Simona Claudia, Tavormina, Giuseppe, Tavormina, Maurilio Giuseppe Maria, Tohen, Mauricio, Tsapakis, Eva Maria, Tikhvatullina, Dina, Ullah, Irfan, Vaidya, Ratnaraj, Vega-Dienstmaier, Johann M, Vrublevska, Jelena, Vukovic, Olivera, Vysotska, Olga, Widiasih, Natalia, Yashikhina, Anna and Smirnova, Daria (2025) Treatment and long-term outcome of mental disorders: the grim picture from a quasi-epidemiological investigation in 54,826 subjects from 40 countries. *Psychiatry Research*, 348. 116459 ISSN 0165-1781

DOI: <https://doi.org/10.1016/j.psychres.2025.116459>

Publisher: Elsevier

Version: Published Version

Downloaded from: <https://e-space.mmu.ac.uk/639565/>

Usage rights:  [Creative Commons: Attribution 4.0](https://creativecommons.org/licenses/by/4.0/)

Additional Information: This is an open access article which appeared in *Psychiatry Research*, published by Elsevier

Enquiries:

If you have questions about this document, contact openresearch@mmu.ac.uk. Please include the URL of the record in e-space. If you believe that your, or a third party's rights have been compromised through this document please see our Take Down policy (available from <https://www.mmu.ac.uk/library/using-the-library/policies-and-guidelines>)



Treatment and long-term outcome of mental disorders: The grim picture from a quasi-epidemiological investigation in 54,826 subjects from 40 countries

Konstantinos N. Fountoulakis^{a,*}, Gregory Karakatsoulis^a, Seri Abraham^{b,c,d}, Kristina Adorjan^e, Helal Uddin Ahmed^f, Renato D. Alarcón^{g,h}, Kiyomi Araiⁱ, Sani Salihu Auwal^{j,k}, Michael Berk^{l,m}, Sarah Levajⁿ, Julio Bobes^{o,p}, Teresa Bobes-Bascaran^{q,r},

* Corresponding author.

E-mail addresses: Kostasfountoulakis@gmail.com (K.N. Fountoulakis), gregkarakatsoulis@gmail.com (G. Karakatsoulis), seri.abraham@nhs.net (S. Abraham), Kristina.Adorjan@med.uni-muenchen.de (K. Adorjan), soton73@gmail.com (H.U. Ahmed), Alarcon.Renato@mayo.edu (R.D. Alarcón), k_arai@shinshu-u.ac.jp (K. Arai), auwal01@yahoo.com (S.S. Auwal), michael.berk@deakin.edu.au (M. Berk), sarahbjedov@gmail.com (S. Levaj), bobes@uniovi.es (J. Bobes), bobesmaria@uniovi.es (T. Bobes-Bascaran), julie.bourgin@gmail.com (J. Bourgin-Duchesnay), brediceancristina@gmail.com (C.A. Bredicean), bukelskis@gmail.com (L. Bukelskis), dr.burkadze@gmail.com (A. Burkadze), indira_ica@hotmail.com (I.I.C. Abud), rcastil4@its.jnj.com (R. Castilla-Puentes), mcetkovich@ineco.org.ar (M. Cetkovich), hectorcolonriveramd@gmail.com (H. Colon-Rivera), rcorral33@gmail.com (R. Corral), carla.cortez.v@upch.pe (C. Cortez-Vergara), piirika.crepin@gmail.com (P. Crepin), domenico.deberardis@aslteramo.it (D. De Berardis), szamora@calvomackenna.cl (S.Z. Delgado), dvdLucena@gmail.com (D. De Lucena), avinashdes888@gmail.com (A. De Sousa), ramonadist@gmail.com (R.D. Stefano), seetaldodd@gmail.com (S. Dodd), elek.livia.priyanka@gmail.com (L.P. Elek), annaelissa.md@gmail.com (A. Elissa), hamzaberta@gmail.com (B. Erdelyi-Hamza), gamze.erzin@gmail.com (G. Erzin), martinjetchevers@gmail.com (M.J. Etchevers), Peter.Falkai@med.uni-muenchen.de (P. Falkai), 6amf@queensu.ca (A. Farcas), ilyafdtv@yandex.ru (I. Fedotov), filatovaviktoria@mail.ru (V. Filatova), nikolasfountoulakis@gmail.com (N.K. Fountoulakis), iryna.frankova@gmail.com (I. Frankova), franza.francesco@virgilio.it (F. Franza), friaspn@gmail.com (P. Frias), tatiana-galako@yandex.ru (T. Galako), cristiangularay@psi.uba.ar (C.J. Garay), lettti@gmail.com (L. Garcia-Álvarez), albert@uniovi.es (M.P. García-Portilla), gonda.xenia@semmelweis.hu (X. Gonda), tomaszmgondek@gmail.com (T.M. Gondek), danielamorera@gmail.com (D.M. González), h Gould@health.ucsd.edu (H. Gould), grandinetti.paolo@gmail.com (P. Grandinetti), doctorgrau@yahoo.com (A. Grau), violetagroudeva@gmail.com (V. Groudeva), michal.hagin@gmail.com (M. Hagin), tkharada77@gmail.com (T. Harada), tasdikhdip@yahoo.com (T.M. Hasan), drsalmi@uitm.edu.my (S. Razali), hilbig.jan@gmail.com (J. Hilbig), sahadat.hossain@juniv.edu (S. Hossain), rosica.iakimova@abv.bg (R. Iakimova), monaawaad99@gmail.com (M. Ibrahim), iftenef@providencecare.ca (F. Iftene), hvala.korolevna@rambler.ru (Y. Ignatenko), matias.irarrazaval@minsal.cl (M. Irarrazaval), zaliha78@uitm.edu.my (Z. Ismail), ismayilova.d@gmail.com (J. Ismayilova), AsafJacobs@gmail.com (A. Jakobs), jakovljevic.miro@yahoo.com (M. Jakovljević), nenad.jaksic@yahoo.com (N. Jakšić), afzalj@gmail.com (A. Javed), helinyilmaz136@gmail.com (H.Y. Kafali), kariabhai117@gmail.com (S. Karia), olga.kazakova.md@gmail.com (O. Kazakova), doakhalifa72@gmail.com (D. Khalifa), 7974247@gmail.com (O. Khaustova), shkoh@ucsd.edu (S. Koh), kopishinskaya@gmail.com (S. Kopishinskaia), sun2003@ukr.net (K. Kosenko), vadonniki96@gmail.com (N.B. Vadon), alishalalljee@gmail.com (A. Lalljee), j.liewig@gmail.com (J. Liewig), maajid72@gmail.com (A. Majid), e.malashonkova@gh-nord-essonne.fr (E. Malashonkova), khameliapsi@gmail.com (K. Malik), Najma.iqbal@uos.edu.pk (N.I. Malik), gulay.mammadzada@gmail.com (G. Mammadzada), bilveshmandalia@gmail.com (B. Mandalia), dmrazzi@psico.med.unipi.it (D. Marazziti), predstojnik.psi@kbc-zagreb.hr (D. Marčinko), stm032@health.ucsd.edu (S. Martinez), eimantasmatiekus@yahoo.com (E. Matiekus), ggmejia@health.ucsd.edu (G. Mejia), memon.roha@gmail.com (R.S. Memon), xarahmeza22@gmail.com (X.E.M. Martínez), dalia.mickeviciute@gmail.com (D. Mickeviciūtė), roumen.milev@queensu.ca (R. Milev), miftahmuhammad101@gmail.com (M. Mohammed), doctor.alex.psiquiatra@gmail.com (A. Molina-López), prof.morozov@gmail.com (P. Morozov), nurusulemuhammad@gmail.com (N.S. Muhammad), filip.mustac@gmail.com (F. Mustac), Mikanaor@mail.tau.ac.il (M.S. Naor), amiraelbatrawy@gmail.com (A. Nassieb), alvydas.navickas@mf.vu.lt (A. Navickas), tarek.okasha@gmail.com (T. Okasha), milena.pandova@gmail.com (M. Pandova), anca.livia.panfil@gmail.com (A.-L. Panfil), p.lilya12@gmail.com (L. Panteleeva), papava.ion@umft.ro (I. Papava), apavlichenko76@gmail.com (A. Pavlichenko), bpejuskovic@hotmail.com (B. Pejuskovic), mariana.pintodacosta@gmail.com (M.P. da Costa), mihailpopkovanat@gmail.com (M. Popkov), popovic.dina@gmail.com (D. Popovic), norjannah@uitm.edu.my (N.J.N. Raduan), fvargas.ra@gmail.com (F.V. Ramírez), erancans@latnet.lv (E. Rancans), azreen@uitm.edu.my (N.A. Hashim), federicorebok@gmail.com (F. Rebok), revewana@gmail.com (A. Rewekant), elena.reyes@unah.edu.hn (E.N.R. Flores), mriverae@usmp.pe (M.T. Rivera-Encinas), frank@uniovi.es (P. Saiz), msanchezdecarmona@mac.com (M.S. de Carmona), davidsaucedomartinez1@gmail.com (D.S. Martínez), annejosaw@uitm.edu.my (J.A. Saw), gsaygili@gmail.com (G. Saygili), p.schneider@klinikum-weissenhof.de (P. Schneider), bhumikarshah47@gmail.com (B. Shah), shirasaka.t@gmail.com (T. Shirasaka), keteveni26@gmail.com (K. Silagadze), sattiradja_96@yahoo.co.id (S. Sitanggang), skugarevsky@gmail.com (O. Skugarevsky), a-spikina@yandex.ru (A. Spikina), sridevi.siramahalingappa@nhs.net (S.S. Mahalingappa), mb.milenkova@yahoo.com (M. Stoyanova), anna.szczegielniak@gmail.com (A. Szczegielniak), simona.tamasan@yahoo.com (S.C. Tamasan), dr.tavormina.g@libero.it (G. Tavormina), mtavormina@virgilio.it (M.G.M. Tavormina), MTohen@salud.unm.edu (M. Tohen), emtsapakis@doctors.org.uk (E.M. Tsapakis), d.tukhvatullina@smd20.qmul.ac.uk (D. Tikhvatullina), Irfanullahecp2@gmail.com (I. Ullah), r.vaidya@newcastle.ac.uk (R. Vaidya), johann.vega.d@upch.pe (J.M. Vega-Dienstmaier), vrublevskaja@inbox.lv (J. Vrublevska), olivukovic@gmail.com (O. Vukovic), uafmed@gmail.com (O. Vysotska), widiasih.1973@yahoo.com (N. Widiasih), akvaraul@mail.ru (A. Yashikhina), daria.smirnova.md.phd@gmail.com (D. Smirnova).

<https://doi.org/10.1016/j.psychres.2025.116459>

Received 5 December 2024; Received in revised form 19 March 2025; Accepted 22 March 2025

Available online 24 March 2025

0165-1781/Crown Copyright © 2025 Published by Elsevier B.V. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Julie Bourgin-Duchesnay^s, Cristina Ana Bredicean^t, Laurynas Bukelskis^u, Akaki Burkadze^{v,w}, Indira Indiana Cabrera Abud^x, Ruby Castilla-Puentes^y, Marcelo Cetkovich^{z,aa}, Hector Colon-Rivera^{ab}, Ricardo Corral^{ac,ad}, Carla Cortez-Vergara^{ae}, Piirika Crepin^{af}, Domenico De Berardis^{ag,ah,ai}, Sergio Zamora Delgado^{aj}, David De Lucena^{ak}, Avinash De Sousa^{al,a}, Ramona Di Stefano^{an}, Seetal Dodd^{l,m,ao}, Livia Priyanka Elek^{ap}, Anna Elissa^{aq}, Berta Erdelyi-Hamza^{ap}, Gamze Erzin^{ar,as}, Martin J. Etchevers^{at}, Peter Falkai^e, Adriana Farcas^{au}, Ilya Fedotov^{av}, Viktoriia Filatova^{aw}, Nikolaos K. Fountoulakis^{ax}, Iryna Frankova^{ay}, Francesco Franza^{az,ba}, Pedro Frias^{bb}, Tatiana Galako^{bc}, Cristian J. Garay^{at}, Leticia Garcia-Álvarez^r, Maria Paz García-Portilla^{o,bd}, Xenia Gonda^{ap}, Tomasz M. Gondek^{be}, Daniela Morera González^{bf}, Hilary Gould^{bg}, Paolo Grandinetti^{ag}, Arturo Grau^{aj,bh}, Violeta Groudeva^{bi}, Michal Hagin^{bj}, Takayuki Harada^{bk}, Tasdik M. Hasan^{bl,bm}, Salmi Razali^{bn}, Jan Hilbig^u, Sahadat Hossain^{bo}, Rossitza Iakimova^{bp}, Mona Ibrahim^{bq}, Felicia Iftene^{br}, Yulia Ignatenko^{bs}, Matias Irarrazaval^{bt}, Zaliha Ismail^{bu}, Jamila Ismayilova^{bv}, Asaf Jakobs^{bw,bx}, Miro Jakovljević^{by}, Nenad Jakšićⁿ, Afzal Javed^{bz,ca,cb}, Helin Yilmaz Kafali^{cc}, Sagar Karia^{al}, Olga Kazakova^{cd}, Doaa Khalifa^{bq}, Olena Khaustova^{ay}, Steve Koh^{bg}, Svetlana Kopishinskaia^{ce,cf}, Korneliia Kosenko^{cg}, Nikolett Beata Vadon^{ap}, Alisha Lalljee^{am}, Justine Liewig^s, Abdul Majid^{ch}, Evgeniia Malashonkova^s, Khamelia Malik^{aq}, Najma Iqbal Malik^{ci}, Gulay Mammadzada^{cj}, Bilvish Mandalia^{am}, Donatella Marazziti^{ck,cl,cm}, Darko Marčinko^{n,by}, Stephanie Martinez^{bg}, Eimantas Matiekus^u, Gabriela Mejia^{bg}, Roha Saeed Memon^{cn}, Xarah Elenne Meza Martínez^{co}, Dalia Mickeviciūtė^{cp}, Roumen Milev^{br}, Muftau Mohammed^{cq}, Alejandro Molina-López^{cr}, Petr Morozov^{cs}, Nuru Suleiman Muhammad^{ct}, Filip Mustaćⁿ, Mika S. Naor^{cu}, Amira Nassieb^{bq}, Alvydas Navickas^u, Tarek Okasha^{bq}, Milena Pandova^{bp}, Anca-Livia Panfil^{cv}, Liliya Panteleeva^{cw}, Ion Papava^t, Alexey Pavlichenko^{bs}, Bojana Pejuskovic^{cx,cy}, Mariana Pinto da Costa^{cz,da,db}, Mikhail Popkov^{dc}, Dina Popovic^{dd}, Nor Jannah Nasution Raduan^{bn}, Francisca Vargas Ramírez^{aj,bh}, Elmars Rancans^{de,df}, Nurul Azreen Hashim^{bn}, Federico Rebok^{dg,dh}, Anna Rewekant^{di}, Elena Ninoska Reyes Flores^{dj}, María Teresa Rivera-Encinas^{dk}, Pilar Saiz^{o,q}, Manuel Sánchez de Carmona^{dl}, David Saucedo Martínez^{dm}, Jo Anne Saw^{bn}, Gökem Saygili^{dn}, Patricia Schneidereit^{do}, Bhumika Shah^{dp}, Tomohiro Shirasaka^{dq}, Ketevan Silagadze^v, Satti Sitanggang^{dr}, Oleg Skugarevsky^{ds}, Anna Spikina^{dt}, Sridevi Sira Mahalingappa^{du}, Maria Stoyanova^{bp}, Anna Szczegieliński^{dv}, Simona Claudia Tamasan^{cu}, Giuseppe Tavormina^{ba,dw,dx}, Maurilio Giuseppe Maria Tavormina^{ba}, Mauricio Tohen^{dy}, Eva Maria Tsapakis^a, Dina Tukhvatullina^{dz}, Irfan Ullah^{ea}, Ratnaraj Vaidya^{eb}, Johann M. Vega-Dienstmaier^{ec}, Jelena Vrublevska^{ed}, Olivera Vukovic^{cy,ee}, Olga Vysotska^{ef}, Natalia Widiasih^{aq}, Anna Yashikhina^{eg}, Daria Smirnova^{eh,ei}

^a 3rd Department of Psychiatry, School of Medicine, Aristotle University of Thessaloniki Greece, Thessaloniki, Greece

^b Pennine Care NHS Foundation Trust, United Kingdom

^c Manchester Metropolitan University, Manchester, United Kingdom

^d Core Psychiatry training, Health Education England North West, United Kingdom

^e Department of Psychiatry and Psychotherapy, LMU University Hospital, Munich, Germany

^f Child Adolescent and Family Psychiatry, National Institute of Mental Health, Dhaka, Bangladesh

^g Section of Psychiatry and Mental Health, Universidad Peruana Cayetano Heredia, Facultad de Medicina Alberto Hurtado, Lima, Peru

^h Department of Psychiatry and Psychology, Mayo Clinic School of Medicine, Rochester, MN, USA

ⁱ School of Medicine and Health Science, Institute of Health Science Shinshu University, Matsumoto, Japan

^j Department of Psychiatry, Bayero University, Kano, Nigeria

^k Aminu Kano Teaching Hospital, Kano, Nigeria

^l IMPACT – the Institute for Mental and Physical Health and Clinical Translation, Deakin University, School of Medicine, Barwon Health, Geelong, Australia

^m Orygen The National Centre of Excellence in Youth Mental Health, Centre for Youth Mental Health, Florey Institute for Neuroscience and Mental Health and the Department of Psychiatry, The University of Melbourne, Melbourne, Australia

ⁿ Department of Psychiatry and Psychological Medicine, University Hospital Centre Zagreb, Zagreb, Croatia

^o Psychiatry Area, Department of Medicine, University of Oviedo, ISPA, INEUROPA. CIBERSAM, Oviedo, Spain

^p Department of Psychiatry, Hospital Universitario Central de Asturias, ISPA, INEUROPA. CIBERSAM, Oviedo, Spain

^q Mental Health Center of La Corredoria, ISPA, INEUROPA. CIBERSAM, Oviedo, Spain

^r Department of Psychology, University of Oviedo, ISPA, INEUROPA. CIBERSAM, Oviedo, Spain

^s Division of Child and Adolescent Psychiatry, Department of Psychiatry, Groupe Hospitalier Nord Essonne, Orsay, France

^t Department of Neuroscience, Discipline of Psychiatry, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania

^u Clinic of Psychiatry, Institute of Clinical Medicine, Medical Faculty, Vilnius University, Vilnius, Lithuania

- ^v Mental Hub, Tbilisi, Georgia
- ^w NGO Healthcare Research and Quality Agency, Tbilisi, Georgia
- ^x Hospital San Juan de Dios Hospital, Guadalajara, Mexico
- ^y Janssen Research and Development, Johnson & Johnson, American Society of Hispanic Psychiatry and WARMI Women Mental Health, Cincinnati, Ohio, USA
- ^z Institute of Translational and Cognitive Neuroscience (INCyT), INECO Foundation, Favaloro University, Buenos Aires, Argentina
- ^{aa} National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina
- ^{ab} APM Board Certified in General Psychiatry and Neurology, Addiction Psychiatry, & Addiction Medicine, UPMC, DDAP, Philadelphia, USA
- ^{ac} Department of Teaching and Research, Hospital Borda, Buenos Aires, Argentina
- ^{ad} University of Buenos Aires, Buenos Aires, Argentina
- ^{ae} Universidad Peruana Cayetano Heredia, Clínica AngloAmericana, Lima, Perú
- ^{af} Sanitaire and Social Union for Accompaniment and Prevention, Center of Ambulatory Psychiatry of Narbonne and Lezignan, Narbonne, France
- ^{ag} Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital "G. Mazzini", ASL Teramo, Teramo, Italy
- ^{ah} School of Nursing, University of L'Aquila, Italy
- ^{ai} Department of Neuroscience and Imaging, School of Psychiatry, University of Chieti, Chieti, Italy
- ^{aj} Child and Adolescent Psychiatry Department, Hospital Luis Calvo Mackenna, Santiago, Chile
- ^{ak} Departamento de Fisiología e Farmacología, Universidade Federal do Ceará, Fortaleza, Ceará, Brazil
- ^{al} Department of Psychiatry, Lokmanya Tilak Municipal Medical College, Mumbai, India
- ^{am} Desousa Foundation, Mumbai, India
- ^{an} Department of Biotechnological and Applied Clinical Sciences, Section of Psychiatry, University of L'Aquila, L'Aquila, Italy
- ^{ao} University Hospital Geelong, Barwon Health, Geelong, Victoria, Australia
- ^{ap} Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary
- ^{aq} Department of Psychiatry, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo National Referral Hospital, Jakarta, Indonesia
- ^{ar} Psychiatry department, Ankara diskapi training and research hospital, Ankara, Turkey
- ^{as} Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, The Netherlands
- ^{at} Faculty of Psychology, University of Buenos Aires (UBA), Buenos Aires, Argentina
- ^{au} Centre of Neuroscience, Queen's University, Providence Care, Kingston, Ontario, Canada
- ^{av} Department of Psychiatry and Psychology Counselling, Ryazan State Medical University, Ryazan, Russia
- ^{aw} State Budgetary Institution of the Rostov Region "Psychoneurological Dispensary", Rostov-on-Don, Russia
- ^{ax} Society for Neurosciences and Rehabilitation (E.N.A.), Thessaloniki Greece
- ^{ay} Medical Psychology, Psychosomatic Medicine and Psychotherapy Department, Bogomolets National Medical University, Kyiv, Ukraine
- ^{az} "Villa dei Pini" Psychiatric Rehabilitation Center, Avellino, Italy
- ^{ba} Psychiatric Studies Centre, Provaglio d'Iseo, Italy
- ^{bb} Hospital Magalhães Lemos, Porto, Portugal
- ^{bc} Department of Psychiatry, Medical Psychology and Drug Abuse, Kyrgyz State Medical Academy, Bishkek, Kyrgyz Republic
- ^{bd} Mental Health Center of La Ería, ISPA, INEUROPA. CIBERSAM, Oviedo, Spain
- ^{be} Institute of Social Studies, University of Lower Silesia, Wrocław, Poland
- ^{bf} Instituto Nacional de Psiquiatría Ramón De la Fuente Muñiz, Mexico City, Mexico
- ^{bg} Department of Psychiatry, University of California San Diego, San Diego, USA
- ^{bh} Universidad Diego Portales, Santiago, Chile
- ^{bi} Department of Diagnostic Imaging, University Hospital Saint Ekaterina, Sofia, Bulgaria
- ^{bj} Forensic Psychiatry Unit, Abarbanel Mental Health Center, Israel
- ^{bk} School of Human Sciences College of Psychology, University of Tsukuba, Tsukuba, Japan
- ^{bl} Department of Primary Care & Mental Health, University of Liverpool, Liverpool, United Kingdom
- ^{bm} Public Health Foundation, Dhaka, Bangladesh
- ^{bn} Department of Psychiatry, Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh, Selangor, Malaysia
- ^{bo} Department of Public Health & Informatics, Jahangirnagar University, Dhaka, Bangladesh
- ^{bp} Second Psychiatric Clinic, University Hospital for Active Treatment in Neurology and Psychiatry "Saint Naum", Sofia, Bulgaria
- ^{bq} Okasha Institute of Psychiatry, Faculty of Medicine, Ain Shams University, Cairo, Egypt
- ^{br} Department of Psychiatry, Queens University, Providence Care, Kingston, Ontario, Canada
- ^{bs} Education center, Mental Health Clinic No 1 n.a. N.A. Alexeev of Moscow Healthcare Department, Moscow, Russia
- ^{bt} Ministry of Health, Millenium Institute for Research in Depression and Personality, Santiago, Chile
- ^{bu} Department of Public Health Medicine, Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh, Selangor, Malaysia
- ^{bv} National Mental Health Center of the Ministry of Health of the Republic of Azerbaijan, Baku, Azerbaijan
- ^{bw} Department of Psychiatry, Westchester Medical Center Health System, Valhalla, NY, USA
- ^{bx} New York Medical College, Valhalla, NY, USA
- ^{by} School of Medicine, University of Zagreb, Zagreb, Croatia
- ^{bz} Institute of Applied Health Research, University of Birmingham, United Kingdom
- ^{ca} Warwick Medical School, University of Warwick, United Kingdom
- ^{cb} Pakistan Psychiatric Research Centre, Fountain House, Lahore, Pakistan
- ^{cc} Isik University, Department of Psychology, Ankara, Turkey
- ^{cd} SwedenPsychiatric clinic of Minsk city, Belarus.
- ^{ce} International Centre for Education and Research in Neuropsychiatry (ICERN), Samara State Medical University, Samara, Russia
- ^{cf} Kirov State Medical University, Kirov, Russia
- ^{cg} Psychiatry, Drug abuse and Psychology Department, Odessa National Medical University, Odessa, Ukraine
- ^{ch} Department of Psychiatry, (Advanced Vertre for Mental Health & Addiction Medicine), SKIMS Medical College, Srinagar, India
- ^{ci} Department of Psychology, University of Sargodha, Sargodha, Pakistan
- ^{cj} Department of Psychiatry, Azerbaijan Medical University, Baku, Azerbaijan
- ^{ck} Department of Clinical and Experimental Medicine, Section of Psychiatry, University of Pisa, Pisa, Italy
- ^{cl} Umicamillus, Saint Camillus International University of Health Sciences, Rome, Italy
- ^{cm} Brain Research Foundation onus, Lucca, Italy
- ^{cn} Jacobi Medical Center - NYCHHC/Albert Einstein College of Medicine, Bronx, NY, USA
- ^{co} Postgraduate Program in Psychiatry, National Autonomous University of Honduras, Tegucigalpa, Honduras
- ^{cp} Private outpatient clinics "JSC InMedica klinika", Vilnius, Lithuania
- ^{cq} Department of Clinical Services, Federal Neuropsychiatric Hospital, Kaduna, Nigeria
- ^{cr} General Office for the Psychiatric Services of the Ministry of Health, Mexico City, Mexico
- ^{cs} Department of Postgraduate Education, Russian National Research Medical University n.a. N.I. Pirogov, Moscow, Russia
- ^{ct} Department of Community Medicine, Ahmadu Bello University Teaching Hospital, Zaria, Nigeria
- ^{cu} Sackler School of Medicine New York State American Program, Tel Aviv University, Tel Aviv-Yafo, Israel
- ^{cv} Compartment of Liaison Psychiatry, "Pius Brinzeu" County Emergency Clinical Hospital, Timisoara, Romania
- ^{cw} Department of Medical Psychology, Psychiatry and Psychotherapy, Kyrgyz-Russian Slavic University, Bishkek, Kyrgyz Republic

- ^{cx} Faculty of Medicine, University of Belgrade, Belgrade, Serbia
- ^{cY} Clinical Department for Stress, Crisis and Affective Disorders, Institute of Mental Health, Belgrade, Serbia
- ^{cZ} South London and Maudsley NHS Foundation Trust, London, United Kingdom
- ^{da} Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom
- ^{db} Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal
- ^{dc} Department of the Introduction to Internal Medicine and Family Medicine, International Higher School of Medicine, Bishkek, Kyrgyz Republic
- ^{dd} University of Barcelona; Bipolar Disorders Program, Hospital Clinic, Barcelona, Catalunya, Spain
- ^{de} Department of Psychiatry and Narcology, Riga Stradins University, Riga, Latvia
- ^{df} National Centre of Mental Health, Riga, Latvia
- ^{dg} Servicio de Emergencia, Acute inpatient Unit, Hospital Moyano, Buenos Aires, Argentina
- ^{dh} Argentine Institute of Clinical Psychiatry (IAPC), Buenos Aires, Argentina
- ^{di} General Psychiatry Unit I, Greater Poland Neuropsychiatric Center, Kościan, Poland
- ^{dj} Department of Psychiatry, National Autonomous University of Honduras, Tegucigalpa, Honduras
- ^{dk} Instituto Nacional de Salud Mental "Honorio Delgado – Hideyo Noguchi", Lima, Perú
- ^{dl} Faculty of Health Sciences, Anahuac University, Mexico City, Mexico
- ^{dm} Department of Psychiatry, Escuela Nacional de Medicina, TEC de Monterrey, Servicio de geriatría, Hospital Universitario "José Eleuterio González" UANL, Monterrey, Nuevo, León, México
- ^{dn} Cognitive Science and Artificial Intelligence Department Tilburg University, the Netherlands
- ^{do} Department of General Psychiatry, Klinikum am Weissenhof Weinsberg, Germany
- ^{dp} DY Patil Medical College, Navi Mumbai, India
- ^{dq} Department of Psychiatry, Teine Keijinkai Medical Center, Sapporo, Japan
- ^{dr} Psychiatric Unit, Pambalah Batung General Hospital, South Kalimantan, Amuntai, Indonesia
- ^{ds} Department of Psychiatry and Medical Psychology, Belarusian State Medical University, Minsk, Belarus
- ^{dt} Saint Petersburg Psychoneurological Dispensary No2, Saint Petersburg, Russia
- ^{du} Derbyshire Healthcare NHS Foundation Trust, The Liasion Team, Royal Derby Hospital, Derby, Derbyshire, United Kingdom
- ^{dv} Department of Psychoprophylaxis, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Poland
- ^{dw} European Depression Association and Italian Association on Depression, Brussels, Belgium
- ^{dx} Bedfordshire Center for Mental Health Research in association with the University of Cambridge, United Kingdom
- ^{dy} Department of Psychiatry and Behavioral Sciences, School of Medicine, University of New Mexico, Albuquerque, New Mexico, USA
- ^{dz} Centre for Global Public Health, Institute of Population Health Sciences, Queen Mary University of London, London, United Kingdom
- ^{ea} Kabir Medical College, Gandhara University, Peshawar, Pakistan
- ^{eb} Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom
- ^{ec} Facultad de Medicina Alberto Hurtado, Universidad Peruana Cayetano Heredia, Lima, Perú
- ^{ed} University of Latvia, Head of Residency Program in Psychiatry, Riga Centre of Psychiatry and Addiction Medicine, Riga, Latvia
- ^{ee} Department for Research and Education, Institute of Mental Health, Belgrade, Serbia
- ^{ef} Educational and Research Center - Ukrainian Family Medicine Training Center, Bogomolets National Medical University, Kyiv, Ukraine
- ^{eg} International Centre for Education and Research in Neuropsychiatry, Samara State Medical University, and Department of Psychiatry, Narcology, Psychotherapy and Clinical Psychology, Samara State Medical University, Samara, Russia
- ^{eh} Institute of Mental Health, Medical University «Reaviz», Samara, Russia
- ^{ei} Psychiatric Studies Centre, European Depression Association, Provaglio d'Iseo, Italy

ARTICLE INFO

Keywords:

Epidemiology
Treatment
Disability
Metabolic syndrome
Outcomes
Mental health
Psychiatry

ABSTRACT

Introduction: This study registered rates of specific treatment options for mental disorders as well as their long-term outcome.

Material and methods: The history of mental disorders was used as a proxy for diagnosis. The data came from the COMET-G study (40 countries; 54,826 subjects, 64.73 % females, 35.45±13.51 years old). The analysis included descriptive statistics, Risk Ratios, *t*-tests, and ANCOVA's.

Results: 24.14 % reported a history of any mental disorder (depression >12 %, non-affective psychosis and Bipolar disorder 1 % each, >20 % self-injury, >10 % had attempted suicide, 7.17 % illegal substance abuse). Most patients were not under any kind of treatment (59.44 %) and most were not receiving treatment as recommended (e.g. 90 % of Bipolar and 2/3 of psychotic patients). No treatment at all and psychotherapy as monotherapy were consistently related to poorer outcomes. In anxiety or depression, only antidepressant monotherapy and benzodiazepines, in Bipolar disorder only antipsychotic monotherapy in males and antidepressant monotherapy in females, and in non-affective psychosis antipsychotics and psychotherapy in females only, were related to good outcomes. No treatment modality was related to a good outcome in those with a history of self-harm, suicidal attempts, or illegal substance use. Only depression and treatment with antidepressants were related to metabolic syndrome.

Discussion: In the community, the overwhelming majority of mental patients do not receive appropriate treatment or, even worse, no treatment at all. The outcome is unfavourable for the majority and only a few selective treatment options seem to make a difference.

1. Introduction

How mental disorders are treated in the real world is not well studied and much of the pharmacoepidemiology of mental disorders is unknown. As a consequence, the data on the real-world outcomes of mental disorders is scant and often restricted to specific populations (Bartova et al., 2016). Thus, while data coming from clinical settings are abundant (Bartova et al., 2016; Mojtabai and Olfson, 2010), and we know the efficacy of therapeutic interventions in mental disorders, we are

unaware of what the real effect is on the global real population of patients, and whether these notionally successful and efficacious treatment options make any difference and influence the global burden of mental disorders.

Mental disorders usually manifest first during adolescent or early adulthood (Eranti et al., 2013; Immonen et al., 2017; Myles et al., 2012; Solmi et al., 2022), and there is a latency from the first onset of symptoms until the diagnosis, measured in years (Medici et al., 2015; Plana-Ripoll et al., 2022; Scott et al., 2018; Solmi et al., 2022). They inflict a

heavy burden on the patients, their families and society as a whole, and despite efforts for early diagnosis and intervention (Angermeyer et al., 2013; Bijjal et al., 2018; Correll et al., 2018; Crump et al., 2013; Fusar-Poli et al., 2017; Kumar et al., 2015a; Schomerus et al., 2012; Taipale et al., 2018; Tiihonen et al., 2011, 2009, 2016; Tiihonen et al., 2006; Torniaainen et al., 2015; Vanasse et al., 2016), individuals suffering from mental disorders have a shorter life expectancy in comparison to that of the general population, and this gap could be as large as 10–15 years (Bagewadi et al., 2016; Bitter et al., 2017; Hjorthoj et al., 2017; Manjunatha et al., 2019; Olsson et al., 2015; Robinson, 2016; Saha et al., 2007; Walker et al., 2015), while disability is huge and rates of remission and rehabilitation are generally unsatisfactory (Jaaskelainen et al., 2013; Suresh et al., 2012).

While the epidemiology of mental disorders is more or less known, at least roughly, the pharmacoepidemiology and the epidemiology of treatment in general, are not well studied and little is known. Most of our knowledge concerns prescription volume, but there is literally no detailed data on the real-world outcome of mental disorders in combination with specific modes of treatment. If such knowledge existed, it would help us to further validate the usefulness of treatment options and to focus public health actions to improve the outcomes.

The **current study aimed** to investigate the rates of specific treatment received by those with mental disorders in the general population as well as their long-term outcomes, using the COMET-G dataset. Secondary aims were the investigation of treatment appropriateness as well as of the relation of specific treatment options with the existence of the metabolic syndrome.

The history of mental disorders was used as a proxy for the diagnosis since all major mental disorders are generally lifelong, episodic, or chronic disorders. Participating in the study was used as a proxy for at least fair functioning.

2. Material and methods

The data came from the COVID-19 MEntal health inTernational for the General population (COMET-G) study, whose main findings have already been published (Fountoulakis et al., 2021a, 2022a, 2022b; Fountoulakis et al., 2022c, 2024; K et al., 2023; Patsali et al., 2020). The full protocol used is available in the webappendix of the first published COMET study (Fountoulakis et al., 2022b) and also in the webappendix of the current study.

The data were collected NNY and anonymously from April 2020 through March 2021. Announcements and advertisements were done on social media and through news sites, but no other organized effort had been undertaken. The first page included a declaration of consent which everybody accepted by continuing with the participation. Approval was initially given by the Ethics Committee of the Faculty of Medicine, Aristotle University of Thessaloniki, Greece, and locally concerning each participating country.

The study sample included data from 40 countries concerning 55,589 responses, but for the current paper, complete data were available for 54,826 subjects (64.73 % females; 34.15 % males; 1.11 % non-binary gender). The contribution of each country and the gender and age composition, as well as details concerning various sociodemographic variables (marital status, education, work, etc.), have been reported (Fountoulakis et al., 2021a, 2022a, 2022b; Fountoulakis et al., 2022c, 2024; K et al., 2023; Patsali et al., 2020).

The study population was self-selected, and the only limitation was age 18 or above. It was not possible to apply post-stratification on the sample as it was done in a previous study (Fountoulakis et al., 2021a), because this would mean that we would need to utilize a similar methodology across many different countries and the population data needed were not available for all countries.

The protocol, which is also available in previous publications (Fountoulakis et al., 2022b), and is also included here in the webappendix, included the registration of already existing (not emerged

during the pandemic) somatic and mental disorders as well as specific treatment modalities with antipsychotics, antidepressants, benzodiazepines, and psychotherapy as monotherapies as well as in combination. The questions B2, B3, B5, B6, and M2 and M3 were used as the source of variables for the current study. The current treatment status was registered but not its history. The COVID-19 pandemic acted as a stressful condition and triggered the emergence of both somatic and mental disorders even de novo, but previous history could serve as a fair approximation for the lifetime prevalence of various medical conditions in the study sample in a quasi-epidemiological frame for the time point just before the pandemic.

A composite score reflecting the presence of hypertension, dyslipidemia, diabetes mellitus, and obesity (0–4) was created and used as a factor reflecting the presence and severity of the metabolic syndrome.

The complete list of mental conditions and treatments registered and their rates are shown in Table 1. All the data were self-reported, no clinical assessment was made, and this constitutes a significant factor for the interpretation of the results.

In terms of diagnostic group, subjects without any history of any mental disorder were assigned to group N, those with any type of history of any mental disorder were assigned to group M, those with a history of anxiety disorder to group A, with depression to group D, with Bipolar disorder to group B, with non-affective psychosis to group P, self-harm to group H, with history of suicidality to group S and those with history of illegal substance use the IS.

Note that self-harm and suicidality had shown a transdiagnostic distribution and therefore although allocation to groups A, D, B, P, and N was mutually exclusive, this was not the case between these groups and groups H and S. Interestingly, a significant number of subjects belonging to the N group also belonged both to the H and S groups. In the comparison between H and S groups with the N group, the Nn group was used, that is the N group with the exclusion of these subjects belonging also to the H and S groups.

The proxy for the outcome is described below in the statistical analysis section

Treatment was registered by the responder and it is self-reported

Treatment appropriateness was defined as a general idea suggesting that antipsychotics are necessary for non-affective psychosis, antidepressants or psychosocial treatment for anxiety and depression and monotherapy or combinations of antipsychotics and antidepressants for Bipolar disorder.

Because of the nature of the data (self-report), the NbN nomenclature was not used in the current paper.

2.1. Statistical analysis

Data only from males and females were used because the overall contribution of non-binary gender in the total study sample was too small to calculate the contribution in age groups divided additionally by treatment options.

- Detailed descriptive statistics were calculated and tables were created
- Subjects were classified into 13 age groups as well as in two major but arbitrary groups, above 45 and below 46.
- Percentages in age groups were compared between diagnostic groups. In total, the percentage of subjects over 45 years old in 6 diagnostic groups by 8 treatment categories and by two genders was compared to the respective percentages of subjects without any mental health history. In total 112 comparisons were performed and the p-level of $p < 0.01$ was accepted as the level of significance.
- Risk Ratios (RR) were calculated as the ratio of the percentage of the pathological state divided by the percentage of the non-pathological state.
- T-test was used to assess the difference between two groups
- Analysis of Covariance (ANCOVA) with Scheffe as a post-hoc test

Table 1
Frequencies (N) and percentages of the total sample (%) of subjects of diagnostic groups; proportions (%) of age groups within each diagnostic group and the relative contribution (ratio) of age groups to the population within each diagnostic group in comparison to the 21–25 age group (standardized as equal to 1). RR corresponds to the risk ratio for subjects over 45 years of age not to participate in the study in comparison to group N.

History of	Group N		any mental disorder		Group A		Group D		Group B		Group P		Other mental disorder		Group H		Group S		Group IS	
	No history of mental disorder		N = 14,334		anxiety disorder		depression		Bipolar disorder		psychosis		disorder		self-harm		Suicide attempt		Illegal substance use	
	N = 40,492		(26.1 4 %)		N = 4267		N = 6943		N = 643		N = 539		N = 1489		N = 11,844		N = 5862		N = 3934	
age	(73.8 5 %)		(7.78 %)		(12.66 %)		(1.17 %)		(0.98 %)		(2.71 %)		(21.6 0 %)		(10.69 %)		(7.17 %)			
	%	ratio	%	ratio	%	ratio	%	ratio	%	ratio	%	ratio	%	ratio	%	ratio	%	ratio	%	ratio
<21	9.83	0.51	9.13	0.46	7.66	0.42	7.85	0.39	18.35	0.69	19.29	0.74	11.62	0.74	16.59	0.61	17.18	0.63	10.32	0.41
21–25	19.32	1.00	19.75	1.00	18.19	1.00	20.14	1.00	26.59	1.00	25.97	1.00	15.65	1.00	27.33	1.00	27.07	1.00	25.47	1.00
26–30	14.30	0.74	16.23	0.82	15.49	0.85	16.92	0.84	15.09	0.57	11.50	0.44	16.32	1.04	16.82	0.62	15.86	0.59	22.19	0.87
31–35	13.55	0.70	14.27	0.72	14.11	0.78	14.60	0.73	12.44	0.47	12.43	0.48	14.17	0.91	12.22	0.45	12.81	0.47	17.92	0.70
36–40	10.69	0.55	11.04	0.56	11.32	0.62	10.86	0.54	7.93	0.30	9.28	0.36	13.90	0.89	8.19	0.30	8.58	0.32	10.22	0.40
41–45	8.65	0.45	8.49	0.43	9.59	0.53	8.20	0.41	5.60	0.21	6.12	0.24	8.60	0.55	5.61	0.21	5.49	0.20	6.10	0.24
46–50	7.10	0.37	6.66	0.34	7.55	0.41	6.63	0.33	6.38	0.24	6.49	0.25	5.71	0.36	4.29	0.16	4.74	0.18	3.51	0.14
51–55	5.41	0.28	5.09	0.26	5.53	0.30	5.23	0.26	2.02	0.08	3.15	0.12	5.64	0.36	2.85	0.10	3.07	0.11	1.80	0.07
56–60	4.51	0.23	4.15	0.21	4.83	0.27	4.29	0.21	2.02	0.08	2.23	0.09	3.76	0.24	2.39	0.09	2.49	0.09	1.12	0.04
61–65	3.23	0.17	2.86	0.14	3.26	0.18	2.97	0.15	2.02	0.08	1.48	0.06	2.35	0.15	1.79	0.07	1.45	0.05	0.58	0.02
66–70	1.85	0.10	1.50	0.08	1.59	0.09	1.45	0.07	1.40	0.05	1.30	0.05	1.61	0.10	1.21	0.04	0.82	0.03	0.53	0.02
71–75	0.82	0.04	0.54	0.03	0.52	0.03	0.65	0.03	0.16	0.01	0.56	0.02	0.27	0.02	0.55	0.02	0.22	0.01	0.18	0.01
>75	0.25	0.01	0.27	0.01	0.37	0.02	0.22	0.01	0.00	0.00	0.19	0.01	0.40	0.03	0.16	0.01	0.20	0.01	0.05	0.00
>45	23.17		21.07		23.65		21.44		14.00		15.40		19.74		13.24		12.99		8.24	
>45 RR			1.10		0.98		1.08		1.66		1.50		1.17		1.75		1.78		2.98	

The core assumption in the analysis that could lead to conclusions on the outcome is that there is a specific age distribution of subjects participating in this kind of online research, meaning that younger ages are over-represented in comparison to a truly representative epidemiological sample with similar clinical characteristics. Thus, the expected age composition is reflected in the age composition of group N. Since the major mental disorders assessed in the current study have a median age at onset at the age of mid-20 s to mid-30 s (Solmi et al., 2022), and since there is a latency time since the first onset of symptoms to diagnosis (Medici et al., 2015; Plana-Ripoll et al., 2022; Scott et al., 2018; Solmi et al., 2022), it is reasonable to assume that the expected age distribution of mental patients participating in the study should be shifted towards greater median age, but this should not affect participation after the age of 45 (arbitrary taken as cut-off). Any reduced participation in any mental patient group after the age of 45 could be an indirect indication or increasing disability or even mortality (loss of functioning or reduced life expectancy). Participation as in group N could be also considered to be an indication of increasing disability or reduced life expectancy since the age at onset implies an increase in median age in the patient groups in comparison to normal subjects. However, there is no sufficient data to precisely estimate the expected age participation in the patient groups. The increased participation in comparison to group N should be considered as an indication of no increasing disability or reduced life expectancy.

The alternative explanation that treatments that do not contribute with a favorable outcome manifest significant attrition due to drop-out from the group and entering another until a suitable treatment option is found should be rejected, because in that case there should be a difference between treatment options, with the most successful ones having the biggest subsamples and high late-age participation in the study.

As a standard for the creation of the pattern of age distribution, the age group of 20–25 was used since this was the biggest age group in group N. Thus, all age groups were standardized as their % size in comparison to the 20–25 age group (equal to 100 %). See Fig. 1 for a detailed explanation.

The statistical package SPSS v.29, provided by the Aristotle University of Thessaloniki, Greece, was used for the analysis. The comparison of proportions and percentages was done with the MedCalc Software v.23.0.6 (Campbell, 2007; Richardson, 2011).

3. Results

3.1. Demographics

The study sample included data from 40 countries. In total data from 54,826 participants from the original study sample of 55,589 subjects (Fountoulakis et al., 2021a, 2022b, 2024), were utilized, since for them, treatment data were available. These subjects were 35.45±13.51 years old; of them 35,489 were females (64.73 %; aged 35.80±13.61) and 18,725 males (34.15 %; aged 34.90±13.29), while 612 declared ‘non-binary gender’ (1.11 %; aged 31.64±13.15). The age means and standard deviations were identical to the original study sample. <6.5 % were older than 60 years.

3.2. Rates of mental disorders

These rates have been reported in detail previously in combination with the rates of somatic disorders (Fountoulakis et al., 2024). Approximately 24.14 % of the study sample had a history of any mental disorder. If self-injury or suicidality were included, the percentage climbs to 39.62 % (15.48 % reported a history of self-harm or suicidal attempts but no formal diagnosis of mental disorder). History of depression (group D) was the most frequently reported mental disorder (>12 %) followed by anxiety (group A; approximately 8 %). History of non-affective psychoses (group P) and Bipolar disorders (group B) were reported by approximately 1 % each. A striking >20 % had a lifetime




Fig. 1. Histogram of age distribution in group N. The age subgroup of 20–25 was the bigger in this group and therefore it was used as the reference to standardize all other age subgroups as their % size in comparison to the 20–25 age group (equal to 100 %).

history of self-injury (group H) and >10 % had attempted suicide (group S) in the past. A history of illegal substance abuse was reported by 7.17 % (Table 1).

3.3. Treatment of mental disorders

The basic results concerning treatment options have been published (Fountoulakis et al., 2024). The treatment options by diagnostic

category and age (above and below 45) at the time of the questionnaire completion are shown in Table 2.

Any treatment was received by 40.56 % of patients with a mental health history, corresponding to 10.60 % of the total study sample. The respective numbers for any pharmacotherapy were 28.75 % and 7.51 %. Within the subsample of persons with mental health history, the rates between males and females receiving any treatment (38.95 % vs. 40.88 %) and any medication (28.57 % vs. 28.71 %) were similar.

Table 2

Percentages of treatment options in the diagnostic subgroups of subjects with a mental health history. For Anxiety, Depression, and ‘other’ one can not be certain whether not receiving any treatment at present represents a problem since some patients might not need treatment after a certain period of time and after the first episode of the disorder. However, this is not the case with Bipolar disorder and non-affective psychosis, for whom one can definitely conclude on their treatment quality.

Treatment option	History of							
	Anxiety	Depression	Bipolar disorder	Non-affective Psychosis	Other	Self-harm	Suicide attempt	Illegal Substance use
Any kind of treatment	33.58	44.61	67.19	67.35	30.69	21.38	25.84	26.35
No treatment of any kind	66.42	55.39	32.81	32.65	69.31	78.62	74.16	73.65
Antipsychotics	1.62	3.28	28.15	36.18	1.07	3.57	6.09	4.78
Antipsychotic monotherapy	*1.22	1.27	7.31	20.04	0.60	1.47	2.92	2.49
Antidepressants	11.09	28.33	43.23	26.90	2.96	10.64	12.74	10.98
Antidepressant monotherapy	7.73	16.89	*15.55	*11.50	1.14	5.46	6.32	5.56
Benzodiazepines	9.89	10.18	19.28	16.33	7.79	5.55	6.32	6.18
Psychotherapy	16.01	18.38	27.68	21.89	22.63	10.16	11.39	13.83
Only Psychotherapy treatment	12.89	10.4	*7.62	*10.20	20.15	6.19	6.87	9.45
Only medication treatment	17.58	26.23	39.5	45.45	8.06	11.22	14.44	12.53
No medication	79.31	65.79	40.44	42.86	89.46	84.81	81.03	83.09
One class of medications	18.84	27.26	36.39	40.82	9.47	11.44	14.09	12.88
Two classes of medications	1.8	6.29	15.24	10.39	0.87	2.89	3.56	2.99
Three classes of medications	0.05	0.65	7.93	5.94	0.20	0.84	1.31	1.02
Mean number of medication classes	0.23	0.42	0.91	0.79	0.11	0.20	0.25	0.22
Mean number of medication classes when under medication	1.09	1.22	1.52	1.40	1.12	1.30	1.33	1.30
Antipsychotic plus antidepressant	0.16	1.83	17.26	10.76	0.40	1.77	2.74	1.83
Antidepressant plus benzodiazepine	1.62	5.69	*12.60	*8.72	0.87	2.63	3.19	2.94
Antipsychotic plus psychotherapy	0.21	1.05	11.66	7.42	0.40	1.16	1.63	1.37
Antidepressant plus psychotherapy	2.16	7.17	*16.80	*7.24	1.61	3.32	3.90	3.66
Benzodiazepines plus psychotherapy	1.34	2.85	*7.47	*5.57	1.48	1.73	1.94	2.06
Treatment not as recommended	**≥66.42	**≥57.71	60.04	43.23	**≥69.31			

* not recommended treatment option.

** not under treatment.

As reported before (Fountoulakis et al., 2024), most patients with mental disorders were not receiving any kind of treatment at all (59.44 %). This was true mainly for anxiety and depression while in the more severe disorders, most patients were under some kind of treatment. Unfortunately, of those patients under treatment, only a small minority received treatment as recommended, e.g. 7.62 % of Bipolar patients and 10.2 % of psychotic patients were treated with psychotherapy alone and respectively 16.8 % and 7.24 % with antidepressant plus psychotherapy and 15.55 % and 11.5 % with antidepressant monotherapy. This pattern impacted the vast majority of patients under treatment in the Bipolar (60.04 % of 67.19 %; that is 9/10 of patients under any kind of treatment) and the psychotic groups (43.23 % of 67.35 %; that is 2/3 of patients under any kind of treatment) (Fountoulakis et al., 2024).

3.4. Long term outcome

In Table 3 the percentage of subjects in the various diagnostic groups by treatment option and age above 45 are included. The p-level corresponds to the comparison of the specific proportion to the corresponding proportion in the group of subjects without any mental disorder. Thus, the percentage of subjects over 45 years old in 6 diagnostic groups by 8 treatment categories and by two genders was compared to the respective percentages of subjects without any mental health history. In total 112 comparisons were performed and the p-level of $p < 0.01$ was accepted as the level of significance. From these comparisons, 29 were non-significant, suggesting a distribution of ages similar to non-mental patients (but also in some cases very small subsamples) and 10 comparisons were significant but suggested that relatively more subjects over 45 years old were included in the patient group in comparison to non-mental patients. Seventy-three comparisons (65.18 %) were significant, reflecting that fewer patients over the age of 45 participated in the study in comparison to normal subjects. This could suggest that in almost 2/3 of diagnosis-by-sex groups, the long-term outcome is poor.

No treatment at all was consistently related to poorer outcome irrespective of gender or diagnostic group. The same was true for psychotherapy as monotherapy. In patients with a history of anxiety or depression, only antidepressant monotherapy and benzodiazepines were related to good outcome. In Bipolar disorder, only antipsychotic monotherapy in males and antidepressant monotherapy in females were related to better outcome. The same treatment options were superior to other options for the opposite sex. In non-affective psychosis, the combination of antipsychotics and psychotherapy in females only, produced the best outcome, while in males they had better effects in comparison to other options. Interestingly, psychotherapy as monotherapy performed worse than no treatment at all in this diagnostic group. In those with a

history of self-harm, suicidal attempts, and illegal substance use no treatment modality was related to a good outcome, but probably benzodiazepines performed better than other treatment modalities.

The complete results are shown in Table 3 and a visual depiction of the data, after assigning to age groups values relative to the 20–25 age group and smoothing the line with the least squares method, is shown in Figs. 2 and 3.

3.5. Metabolic syndrome

Patients with psychiatric disorders had a slightly higher but significant composite metabolic score in comparison to the general population (group M vs. group N; 0.09 ± 0.32 vs. 0.08 ± 0.29 , $t = -3.529$, $df: 54,824$, $p < 0.001$). ANCOVA with diagnostic groups as grouping variable and age and gender (males and females) as covariates produced a significant effect for diagnosis ($SS=2.993$, $df:5$, $MS: 0.598$, $F: 6.850$; $p < 0.0001$). The post-hoc test revealed that at $p < 0.01$, the significant difference concerned group D vs group N only. ANCOVA of group H vs. group Nn with age and gender as covariates returned no significant results ($SS=0.024$, $df:1$, $MS: 0.024$, $F: 0.294$; $p = 0.587$). Similarly non-significant was the comparison of group S vs. group Nn ($SS=0.233$, $df:1$, $MS: 0.233$, $F: 2.802$; $p = 0.094$). The ANCOVA of treatment options as a grouping variable with age and gender as covariates returned significant results ($SS=4.795$, $df:5$, $MS: 0.951$, $F: 11.016$; $p < 0.001$). The post-hoc analysis revealed that this difference concerned only antidepressant monotherapy or in combination with antipsychotics vs. all the other options (at $p < 0.01$; Table 3).

ANCOVA with diagnostic group by treatment as grouping variable (see Table 3 for grouping) age and gender (males and females) as covariates produced significant effect for diagnosis by treatment groups ($SS=4.795$, $df:5$, $MS: 0.959$, $F: 11.016$; $p < 0.0001$). The post-hoc test revealed that at $p < 0.001$, the significant differences concerned antidepressant monotherapy (irrespective of diagnosis) vs. all other groups and no treatment vs. only psychotherapy. The means and standard deviations for each diagnosis by treatment group are shown in Table 4. A visual depiction of the composite metabolic score in the various diagnostic groups is shown in Fig. 4.

4. Discussion

The results of this study suggest that >39 % reported a history of any mental disorder, including history of self-injury or suicidality. A history of depression was reported by >12 % while non-affective psychosis and Bipolar disorder were present in approximately 1 % each. A history of illegal substance abuse was reported by 7.17 %. Interestingly, the

Table 3
Mean and standard deviation of the composite metabolic score for each treatment option.

treatment category	gender	N	age		metabolic syndrome composite score		RR
			mean	SD	mean	SD	
No mental health history	females	25,050	35.92	13.80	0.08	0.29	1.00
	males	15,061	35.14	13.40	0.09	0.31	1.00
Mental health history but no treatment	females	4191	34.62	13.05	0.08	0.31	1.06
	males	1347	34.28	12.62	0.12	0.37	1.21
Antidepressant monotherapy	females	1253	40.15	14.22	0.13	0.41	1.40
	males	412	36.59	14.24	0.18	0.48	1.55
Antipsychotic monotherapy	females	126	34.26	13.20	0.06	0.24	0.84
	males	163	31.33	13.00	0.06	0.24	0.78
Only psychotherapy	females	1271	33.86	10.84	0.06	0.24	0.84
	males	380	32.57	11.87	0.08	0.31	1.01
Antipsychotic plus antidepressant	females	205	32.23	12.06	0.08	0.29	1.01
	males	94	31.83	10.76	0.06	0.29	0.92
Various treatments	females	3393	35.81	13.28	0.08	0.29	1.01
	males	1268	33.62	12.79	0.10	0.33	1.08

The ANCOVA of treatment options as a grouping variable with age and gender as covariates returned significant results ($SS=4.795$, $df:5$, $MS: 0.951$, $F: 11.016$; $p < 0.001$). The post-hoc analysis revealed that this difference concerned only antidepressant monotherapy or in combination with antipsychotics vs. all the other options at $p < 0.01$.




Fig. 2. Visualization of the age distribution data in the diagnostic by treatment groups for groups A, D, B, and P after assigning to age subgroups values relative to the 20–25 age group and smoothing the line with the least squares method.




Fig. 3. Visualization of the age distribution data in the various diagnostic by treatment groups after assigning to age subgroups values relative to the 20–25 age group for groups H, S, and IS, and smoothing the line with the least squares method.

majority of patients with mental disorders were not receiving any kind of treatment at all (59.44 %), and additionally, of those patients under treatment, the vast majority were not receiving treatment as recommended (90 % of treated patients with Bipolar disorder and 2/3 of psychotic patients). The analysis of the proportion of patients over 45 years of age participating in the current study suggested that no treatment at all was consistently related to poorer outcomes irrespective of gender or diagnostic group. The same was true for psychotherapy as monotherapy. The above results should be considered only by bearing in mind that they were not derived either from blind controlled trials or from formal epidemiological datasets. Instead, they could reflect some biases and confounding by indication in methodology.

In patients with a history of anxiety or depression, only antidepressant monotherapy and benzodiazepines were related to good outcome. In Bipolar disorder, only antipsychotic monotherapy in males and antidepressant monotherapy in females were related to better outcome.

The same treatment options were superior to others in the opposite sex. In non-affective psychosis, the combination of antipsychotics and psychotherapy in females only, produced the best outcome, while in males they had better effects in comparison to other options. Interestingly, psychotherapy as monotherapy performed worse than no treatment at all in this diagnostic group. In a history of self-harm and suicidal attempts, no treatment modality was related to a good outcome, but probably benzodiazepines performed better than other treatment modalities.

Patients with a history of depression had a significantly higher metabolic syndrome burden. This was at least partially associated with treatment with antidepressants. No other medication was related to the metabolic syndrome.

Some treatments by sex groups included a very low number of subjects (males with antipsychotic monotherapy in Bipolar disorder or without any kind of treatment in non-affective psychosis). This means

Table 4

Percentage of subjects in the various diagnostic groups by treatment option and classified into two age groups with 45 years as the cut-off. The p-level corresponds to the comparison of the specific proportion to that of group N and specifically for groups H and S with group Nn. The p-level of $p < 0.01$ was accepted as the level of significance.

		N, aged <46	N, aged >45	% >45	RR	p-level
Total study sample (N = 54,214, 100 %)	females	27,016	8473	23.87		
	males	14,851	3874	20.69		
Normal (N = 4011, 73.98 %)	females	18,890	6160	24.59	1.00	
	males	11,867	3194	21.21	1.00	
Anxiety (N=4216, 7.78 %)						
Only psychotherapy	females	357	64	15.20	0.62	<0.001
	males	93	24	20.51	0.97	0.895
No treatment	females	1331	385	22.44	0.91	0.006
	males	419	88	17.36	0.82	0.003
Both antidepressants and psychotherapy	females	58	13	18.31	0.74	<0.001
	males	16	5	23.81	1.12	0.051
Both antipsychotics and psychotherapy	females	3	1	25.00	1.02	0.607
	males	5	0	0.00	0.00	<0.001
Both antidepressants and antipsychotics	females	3	0	0.00	0.00	<0.001
	males	4	0	0.00	0.00	<0.001
Antipsychotic monotherapy	females	16	5	23.81	0.97	0.326
	males	27	1	3.57	0.17	<0.001
Antidepressant monotherapy	females	153	94	*38.06	1.55	<0.001
	males	57	25	*30.49	1.44	<0.001
Benzodiazepines	females	195	141	*41.96	1.71	<0.001
	males	52	31	*37.35	1.76	<0.001
Depression (N = 6858, 12.65 %)						
Only psychotherapy	females	501	60	10.70	0.43	<0.001
	males	126	20	13.70	0.65	<0.001
No treatment	females	1426	366	20.42	0.83	<0.001
	males	442	108	19.64	0.93	0.146
Both antidepressants and psychotherapy	females	350	61	14.84	0.60	<0.001
	males	60	18	23.08	1.09	0.085
Both antipsychotics and psychotherapy	females	48	7	12.73	0.52	<0.001
	males	13	3	18.75	0.88	0.022
Both antidepressants and antipsychotics	females	75	12	13.79	0.56	<0.001
	males	34	3	8.11	0.38	<0.001
Antipsychotic monotherapy	females	32	6	15.79	0.64	<0.001
	males	44	1	2.22	0.10	<0.001
Antidepressant monotherapy	females	558	335	*37.51	1.53	<0.001
	males	195	74	27.51	1.30	0.011
Benzodiazepines	females	383	177	*31.61	1.29	<0.001
	males	87	50	*36.50	1.72	<0.001
Bipolar disorder (N = 612, 1.13 %)						
Only psychotherapy	females	24	2	7.69	0.31	<0.001
	males	19	2	9.52	0.45	<0.001
No treatment	females	88	7	7.37	0.30	<0.001
	males	35	3	7.89	0.37	<0.001
Both antidepressants and psychotherapy	females	63	5	7.35	0.30	<0.001
	males	34	1	2.86	0.13	<0.001
Both antipsychotics and psychotherapy	females	39	4	9.30	0.38	<0.001
	males	24	0	0.00	0.00	<0.001
Both antidepressants and antipsychotics	females	67	8	10.67	0.43	<0.001
	males	30	1	3.23	0.15	<0.001
Antipsychotic monotherapy	females	21	6	22.22	0.90	0.272
	males	8	11	*57.89	2.73	<0.001

Table 4 (continued)

		N, aged <46	N, aged >45	% >45	RR	p-level
Antidepressant monotherapy	females	40	21	*34.43	1.40	<0.001
	males	25	6	19.35	0.91	0.512
Benzodiazepines	females	63	13	17.11	0.70	<0.001
	males	36	4	10.00	0.47	<0.001
Non-affective Psychosis (N = 517, 0.95 %)						
Only psychotherapy	females	18	2	10.00	0.41	<0.001
	males	30	3	9.09	0.43	<0.001
No treatment	females	40	7	14.89	0.61	<0.001
	males	22	8	26.67	1.26	0.040
Both antidepressants and psychotherapy	females	14	3	17.65	0.72	0.007
	males	18	4	18.18	0.86	0.253
Both antipsychotics and psychotherapy	females	13	9	*40.91	1.66	<0.001
	males	13	5	27.78	1.31	0.013
Both antidepressants and antipsychotics	females	27	8	22.86	0.93	0.505
	males	15	5	25.00	1.18	0.154
Antipsychotic monotherapy	females	28	8	22.22	0.90	0.361
	males	55	10	15.38	0.73	0.028
Antidepressant monotherapy	females	36	3	7.69	0.31	<0.001
	males	21	2	8.70	0.41	<0.001
Benzodiazepines	females	40	12	23.08	0.94	0.561
	males	27	7	20.59	0.97	0.815
Self-harm (N = 11,270, 20.79 %)						
Only psychotherapy	females	467	37	7.34	0.30	<0.001
	males	184	16	8.00	0.38	<0.001
No treatment	females	1200	102	7.83	0.32	<0.001
	males	345	37	9.69	0.46	<0.001
Both antidepressants and psychotherapy	females	275	32	10.42	0.42	<0.001
	males	57	14	19.72	0.93	0.043
Both antipsychotics and psychotherapy	females	84	7	7.69	0.31	<0.001
	males	34	5	12.82	0.60	<0.001
Both antidepressants and antipsychotics	females	138	8	5.48	0.22	<0.001
	males	46	7	13.21	0.62	<0.001
Antipsychotic monotherapy	females	61	4	6.15	0.25	<0.001
	males	94	6	6.00	0.28	<0.001
Antidepressant monotherapy	females	374	98	20.76	0.84	<0.001
	males	136	24	15.00	0.71	<0.001
Benzodiazepines	females	381	123	24.40	0.99	0.687
	males	104	27	20.61	0.97	0.416
Suicidal attempt (N = 5713, 10.54 %)						
Only psychotherapy	females	210	23	9.87	0.40	<0.001
	males	137	15	9.87	0.47	<0.001
No treatment	females	559	89	13.73	0.56	<0.001
	males	188	30	13.76	0.65	<0.001
Both antidepressants and psychotherapy	females	144	25	14.79	0.60	<0.001
	males	44	7	13.73	0.65	<0.001
Both antipsychotics and psychotherapy	females	55	7	11.29	0.46	<0.001
	males	26	3	10.34	0.49	<0.001
Both antidepressants and antipsychotics	females	99	12	10.81	0.44	<0.001
	males	36	6	14.29	0.67	<0.001
Antipsychotic monotherapy	females	51	4	7.27	0.30	<0.001
	males	95	12	11.21	0.53	<0.001
Antidepressant monotherapy	females	201	57	22.09	0.90	<0.001
	males	95	11	10.38	0.49	<0.001
Benzodiazepines	females	196	65	24.90	1.01	0.616
	males	75	18	19.35	0.91	0.054
Illegal substance use N = 3934 (7.17 %)						
Only psychotherapy	females	208	11	5.02	0.20	<0.001
	males	117	15	11.36	0.54	0.008
No treatment	females	1304	103	7.32	0.30	<0.001

(continued on next page)

Table 4 (continued)

		N, aged <46	N, aged >45	% >45	RR	p-level
Both antidepressants and psychotherapy	males	1315	118	8.23	0.39	<0.001
	females	86	3	3.37	0.14	<0.001
	males	41	6	12.77	0.60	0.018
Both antipsychotics and psychotherapy	females	24	0	0.00	0.00	0.006
	males	23	1	4.17	0.20	0.045
Both antidepressants and antipsychotics	females	34	1	2.86	0.12	0.004
	males	32	1	3.03	0.14	0.123
Antipsychotic monotherapy	females	26	2	7.14	0.29	0.037
	males	62	1	1.59	0.07	<0.001
Antidepressant monotherapy	females	130	11	7.80	0.32	<0.001
	males	70	5	6.67	0.31	0.002
Benzodiazepines	females	126	12	8.70	0.35	<0.001
	males	80	10	11.11	0.52	0.025

* The proportion of subjects aged >45 is higher than in the population without a history of mental disorder.

that conclusions could not be considered as solid, however, these groups come from a huge quasi-epidemiological sample of >50,000 persons.

The interpretation of the above results should take into consideration the major factors that determine the findings (apart from methodological design). Disability and premature death is the factor that determines the age distribution horizontally across all subgroups of patients in the study sample, by reducing the participation in advanced age groups. Another major factor that affects the age distribution is the age at onset and the latency from onset to diagnosis. This shifts the peak age away from the early 20 s and close to the early 30 s (see Fig. 5). In general it is accepted that the diagnosis follows the onset of symptoms with a latency time of 5–10 years depending on the specific disorder, but this latency tends to be shorter and subsequently, a diagnosis of mental disorders tends to occur sooner in recent years than the past (Medici et al., 2015; Plana-Ripoll et al., 2022; Scott et al., 2018; Solmi et al., 2022). This is probably a result of long-term efforts and campaigning against stigma and the usefulness of early diagnosis and intervention (Angermeyer et al., 2013; Schomerus et al., 2012). However, the data on the age at onset and subsequently of diagnosis are conflicting, and important methodological limitations make any conclusions problematic (Chen et al., 2018; Fagerlund et al., 2021; Fountoulakis et al., 2019, 2021b; Jones, 2013; Xu et al., 2020), despite the several meta-analyses that exist (Eranti et al., 2013; Immonen et al., 2017; Myles et al., 2012; Solmi et al., 2022). The most recent and reliable meta-analysis (Solmi et al., 2022) reported a median age at onset of 25 for schizophrenia, 30 for unipolar depression, 33 for Bipolar disorder, 13–32 for anxiety disorders depending on the specific disorder, and 22 for cannabis use. The proportion of patients at the age of 25 was 50 % for non-affective psychosis, 47 % for unipolar depression, 70 % for Bipolar disorder, 30–80 % for anxiety disorders, and 80 % for substance use.

Diagnosis was delayed as long as 4 years for depression and 1 year for Bipolar disorder. The respective period varied for anxiety while it was very short for non-affective psychosis. In Fig. 5 the distributions of age at onset for various mental disorders are shown (Solmi et al., 2022). On the other hand, individuals suffering from mental disorders have a shorter life expectancy in comparison to that of the general population, and this loss could be as big as 10–15 years (Hjorthøj et al., 2017; Saha et al., 2007; Walker et al., 2015). Since two opposite trends exist (one is the introduction of new cases by passing the years (incidence) and the other is the drop-out because of loss of functioning and shorter life expectancy), the net outcome is unknown.

One of the aims of the study was to investigate whether there is any data in support of a different long-term outcome for different diagnostic




Fig. 4. Metabolic composite score in the four major mental disorders by treatment option vs. age subgroup.

groups receiving different treatment options. It is known that proper treatment especially as early as possible could improve the outcome and reduce the loss in life expectancy and also it could sustain better functioning (Correll et al., 2018; Fusar-Poli et al., 2017; Reddy et al., 2017).

Major mental illnesses accounted for 24.14 % of the total study sample and this is like the 23.1 % reported by the NIMH and the 2022 NSDUH Annual National Report for 2022. Interestingly, the majority of patients with mental disorders were not receiving any kind of treatment at all (59.44 %), and this is in contrast to the NIMH 2022 NSDUH Annual National Report as well as previous reports (Kessler et al., 2001; Narrow




Fig. 5. The distributions of age at onset for various mental disorders (after permission from Solmi et al. (2022) Mol Psychiatry 27,281–295).

et al., 2000), that suggest only one-third to less than half of patients are not under treatment. This could possibly reflect a difference between the US (and possibly Europe, Canada, etc.) and the rest of the world (<https://www.nimh.nih.gov/health/statistics/mental-illness>). Any treatment was received by 40.56 % of patients with a mental health history, corresponding to 10.60 % of the total study sample. The respected numbers for any pharmacotherapy were 28.75 % and 7.51 %. Within the subsample of persons with mental health history, the rates between males and females receiving any treatment (38.95 % vs. 40.88 %) and any medication (28.57 % vs. 28.71 %) were similar. These findings are half in size in comparison to the US CDC report for 2021–2023 (<https://www.statista.com/statistics/252316/type-of-mental-health-service-used-by-us-adults-since-2002/>) and their consistency (same findings for all therapies and for medication separately and same finding for both sexes) adds to their reliability and validity. Additionally, in our study, of those patients under treatment, the vast majority were not receiving treatment as recommended (90 % of patients treated for Bipolar disorder and 2/3 of psychotic patients).

The finding that no treatment at all leads to poor outcome was expected. This is not the case however with psychotherapy when used as monotherapy which was almost always related to a worse long-term outcome. It would be expected that at least in some diagnostic groups (e.g. anxiety, depression) psychotherapy should perform better than no treatment at all (Kamenov et al., 2017; Munder et al., 2019). In non-affective psychosis, psychotherapy performed worse even in comparison to no treatment at all. This finding is in sharp contrast with the literature which supports at least some efficacy for psychotherapy in psychotic patients, especially in combination with pharmacotherapy (Haram et al., 2019; Health Quality, 2018; Turner et al., 2014). However, it should be noted that the literature on psychotherapy seems flawed (unblinded trials, super-selective samples, investigators with a strong allegiance to the specific psychotherapy, lack of adequate placebo condition or comparison to nocebo conditions such as waitlist, etc.) (Fountoulakis and Tsapakis, 2024). One could argue, however, that under the umbrella ‘psychotherapy’, patients could include any kind of unsystematic regular contact with a therapist, rather than specific and proper psychotherapy per se. However, it is difficult to argue in favor of this in those cases in our study sample that reported psychotherapy as monotherapy. Interestingly, in depression, the rates of monotherapy with psychotherapy or antidepressants and their combination were roughly equal, while in anxiety psychotherapy monotherapy was received by most subjects under treatment.

The treatment rates for depression reported here are similar (though

a little lower) to what is reported in the literature e.g. by >75 % of patients even in homeless populations (Bartova et al., 2016) or approximately 50 % in depressives living with family (Olie et al., 2002). In anxiety and depression, the only treatments that seem to relate with a favorable outcome are antidepressant monotherapy and benzodiazepines, and interestingly they seem to exert an effect similar in size. The lack of better outcome for the combination of antidepressants with psychotherapy is not in accordance with the literature (Kamenov et al., 2017).

The literature reports that only one-third of Bipolar patients were not getting treatment (1993). While recent data reflect a trend towards increasing antipsychotic and antidepressant use in Bipolar disorder up to 50 % of patients in the US (Dimellis and Fountoulakis, 2015; Rhee et al., 2020), this is not in accord with our finding of 28.15 % antipsychotic use. Similarly, antidepressant monotherapy was reported by 15.55 which is lower than the 25 % reported by other studies (Lyll et al., 2019). Antipsychotic monotherapy was also lower with 7.31 vs. 13 % in the literature while the combination of an antipsychotic plus an antidepressant was almost triple than that reported in the literature (17.26 vs. 6.2 %) (Lyll et al., 2019). In Scandinavia, antipsychotic use in Bipolar disorder was reported to be as high as 50 % and antidepressants as high as 30 % (Kessing et al., 2016). Much lower rates were reported in the UK and Hong Kong (Ng et al., 2021). Our findings suggest that in Bipolar disorder a favorable outcome is related to antipsychotics in males and antidepressants in females, possibly reflecting differences in predominant polarity (Carvalho et al., 2014a, 2014b; Dell’Osso et al., 2021; Nivoli et al., 2011; Rasgon et al., 2005).

In our dataset, 36.18 % of patients with a history of non-affective psychosis were receiving antipsychotics and this is very close to the report by the CATIE study, that 74 % of patients discontinuing treatment within the first year with 30 % doing this in the basis of personal choice for unknown reasons (Lieberman et al., 2005), but in contrast with other studies that report that >2/3 of patients receive some kind of proper treatment (1993; Olfson et al., 2010; Vanelli et al., 2001), but most of these reports concern clinical samples. Our data concerning the use of antidepressants in non-affective psychosis are in accord with the literature (Galling et al., 2018; Himelhoch et al., 2012) and especially the CATIE study (Chakos et al., 2006). Overall, the antidepressant use in non-affective psychosis is equivocal (Buchanan et al., 2010; Lehman et al., 2004; Sepehry et al., 2007; Silver, 2003; Singh et al., 2010) and only a few data exist (Addington et al., 2002; Daniel et al., 1994; Galling et al., 2018; Mojtabai and Olfson, 2010; Mulholland et al., 2003; Sepehry et al., 2007; Whitehead et al., 1996). Our results suggest that in

non-affective psychosis it is the combination of antipsychotics and psychotherapy that is related to better outcome, but this only in females. This probably reflects a more benign subgroup of patients that remain affiliated with the health care system and adhere to treatment with antipsychotics, and it is also in accord with a better outcome for females (Kohler et al., 2009; Ochoa et al., 2012). Unfortunately, all treatment options were similar to non-treatment concerning self-harm and suicidal attempts, with only benzodiazepines having some effect.

A history of illegal substance use was reported by 7.17 %. Similarly to the other findings, this is half of what has been reported by the NCDAS for the US for 2020 (<https://drugabusestatistics.org/>) and the SAMHSA for 2023 (<https://www.hhs.gov/about/news/2024/07/30/samhsa-releases-annual-national-survey-drug-use-and-health.html>). However treatment rates are almost identical between our findings and these reports. Treatment and outcome are highly personalized for this group of patients and no reliable epidemiological data exist concerning the long-term outcome (Greenfield et al., 2007; Okrant et al., 2023). There are at least some data suggesting that psychotic patients might use alcohol less than the general population (Kumar et al., 2015b) and comorbidity plays a major role in observed rates (Udupi et al., 2018).

The finding that the metabolic syndrome is related to depression and antidepressants is in accord with the literature (Gramaglia et al., 2018; Kumar et al., 2013; Penninx and Lange, 2018), however, the finding that non-affective psychosis and antipsychotics are not related is not in accord with the literature which suggests that antipsychotics cause more problems in this area (Bernardo et al., 2021; Carli et al., 2021; Penninx and Lange, 2018; Pillinger et al., 2020; Rawat et al., 2018; Zhang et al., 2021). In general, major adverse health outcomes with antidepressants are not supported by the literature (Dragioti et al., 2019).

The current paper reports on the prevalence of mental disorders and their treatment in a large convenient sample from 40 countries. The first question is how appropriate this study sample is for such a quasi-epidemiological study, and subsequently, how reliable and how valid are the rates that are reported. Since the data were obtained by self-reporting from a self-selected sample, the only way to assess validity is to compare the findings concerning a specific topic with already known answers on this topic.

Overall, the findings of the current study are generally in accord with the literature concerning the prevalence of major mental disorders, including anxiety (Bourdon et al., 1992; Wittchen and Jacobi, 2005), depression (Goodwin et al., 2022; Lim et al., 2018), Bipolar disorder (Bebbington and Ramana, 1995; Fountoulakis, 2015; Merikangas et al., 2011; Pini et al., 2005), and psychosis (Eaton, 1991; McGrath et al., 2008), as well as self-injury (Agle and Xiao, 2021; Cipriano et al., 2017; Lucena et al., 2022). While the history of suicidal attempts was found to pass 10 %, the rates reported in the literature vary between 2 and 5 % (Borges et al., 2006, 2010; Fairweather-Schmidt and Anstey, 2012; Fountoulakis et al., 2012; Kessler et al., 1999; Nock et al., 2008; Schmidtke et al., 1996), however, the variability is great and it seems that selective retrieval of memories is involved. This is evident since studies in adolescents report rates around 20 % (Liu et al., 2018; Van Meter et al., 2023) while surveys in middle-aged individuals report much lower lifetime rates. This general agreement with the literature supports the validity of the study sample and the results of the current study.

The finding that most patients were not receiving treatment at all was more or less expected. However, the finding that above 90 % of Bipolar patients and 75 % of patients with non-affective psychosis receive an inappropriate treatment or do not receive any treatment at all, was alarming, but not unexpected since similar reports can be found in the literature (Fond et al., 2019). If these severe mental disorders that have the most clear-cut treatment guidelines are treated so inadequately, then it is likely other mental disorders with less robust guidelines or in the case of milder and not 'classical' manifestations of mental disorders, the lack of treatment or incorrect treatment is probably widespread. It was also expected to find that mental disorders in general

cause significant disability and reduce life expectancy. These observations also reject an alternative explanation of our findings, that is, treatments that do not contribute to a favorable outcome manifest significant attrition due to the drop-out of patients from the group only to join another until a suitable treatment option is found.

The finding that antipsychotics were unrelated to the development of metabolic syndrome was also unexpected (Correll, 2007; Fenton and Chavez, 2006; Suppes et al., 2007). The finding that patients with psychiatric disorders have more frequent metabolic syndrome is in accord with the literature (Correll, 2007). Our results point to the urgent need for better training of psychiatrists as well as of all mental health professionals and GPs in the treatment of patients with psychiatric disorders, especially of the most severely ill. Training based on modern technocratic methods and ways of clinical work, which is standard in the rest of medicine, seems to be an unmet need in Psychiatry and it takes a toll on patients. Even if the results of the current study overestimate the problem and are influenced by residual confounding, still there seems to be much room for improvement concerning the treatment and the outcome of patients with psychiatric disorders at an international level and especially at the level of primary care (Ibrahim et al., 2021; Kumar et al., 2017).

5. Conclusion

Unfortunately, most of mental patients might not receive appropriate treatment according to standard recommendations, or, even worse, no treatment at all, and the outcome is unfavorable for the majority of patients. However, a few selective treatment options seem to make a difference and improve functioning and/or life expectancy. It seems that the outcomes could be relatively good in those who continue the prescribed treatment (both medical and psychosocial). The above points to the importance of better teaching psychiatry and mental health in medical schools and also to the need for more technocratically oriented training of psychiatric residents and also during life-long education and training.

5.1. Strengths and limitations

The strengths of the current paper include the large number of people who filled out the questionnaire and the large bulk of information obtained. The major limitation was that the data were obtained anonymously online through the self-selection of the responders, via self-report without any clinical or laboratory investigation. The utilization of 'personal medical history' was a fair approximation for the morbidity of the study sample without the effect of the pandemic, but still, it is an approximation open to debate. Also, the use of age distribution above 45 as a proxy for general functioning and life expectancy is a fair proxy, however, the interpretation and the generalization of results should be done with caution. There is always a risk of selection bias and confounding by indication in studies of such methodology.

Funding

None.

CRedit authorship contribution statement

Konstantinos N. Fountoulakis: Writing – review & editing, Writing – original draft, Supervision, Project administration, Methodology, Formal analysis, Data curation, Conceptualization. **Gregory Karakatsoulis:** . **Seri Abraham:** . **Kristina Adorjan:** . **Helal Uddin Ahmed:** . **Renato D. Alarcón:** . **Kiyomi Arai:** . **Sani Salihu Auwal:** . **Michael Berk:** . **Sarah Levaj:** . **Julio Bobes:** . **Teresa Bobes-Bascaran:** . **Julie Bourgin-Duchesnay:** . **Cristina Ana Bredicean:** . **Laurynas Bukelskis:** . **Akaki Burkadze:** . **Indira Indiana Cabrera Abud:** . **Ruby Castilla-Puentes:** . **Marcelo Cetkovich:** . **Hector Colon-Rivera:** . **Ricardo**

Corral : Carla Cortez-Vergara : Piirika Crepin : Domenico De Berardis : Sergio Zamora Delgado : David De Lucena : Avinash De Sousa : Ramona Di Stefano : Seetal Dodd : Livia Priyanka Elek : Anna Elissa : Berta Erdelyi-Hamza : Gamze Erzin : Martin J. Etchevers : Peter Falkai : Adriana Farcas : Ilya Fedotov : Viktoriia Filatova : Nikolaos K. Fountoulakis : Iryna Frankova : Francesco Franza : Pedro Frias : Tatiana Galako : Cristian J. Garay : Leticia García-Álvarez : Maria Paz García-Portilla : Xenia Gonda : Tomasz M. Gondek : Daniela Morera González : Hilary Gould : Paolo Grandinetti : Arturo Grau : Violeta Groudeva : Michal Hagin : Takayuki Harada : Tasdik M. Hasan : Salmi Razali : Jan Hilbig : Sahadat Hossain : Rossitza Iakimova : Mona Ibrahim : Felicia Iftene : Yulia Ignatenko : Matias Irarrazaval : Zaliha Ismail : Jamila Ismayilova : Asaf Jakobs : Miro Jakovljević : Nenad Jakšić : Afzal Javed : Helin Yilmaz Kafali : Sagar Karia : Olga Kazakova : Doaa Khalifa : Olena Khaustova : Steve Koh : Svetlana Kopishinskaya : Korneliia Kosenko : Nikolett Beata Vadon : Alisha Lalljee : Justine Liewig : Abdul Majid : Evgeniia Malashonkova : Khamelia Malik : Najma Iqbal Malik : Gulay Mammadzada : Bilvesh Mandalia : Donatella Marazziti : Darko Marčinko : Stephanie Martinez : Eimantas Matiekus : Gabriela Mejia : Roha Saeed Memon : Xarah Elenne Meza Martínez : Dalia Mickeviciūtė : Roumen Milev : Muftau Mohammed : Alejandro Molina-López : Petr Morozov : Nuru Suleiman Muhammad : Filip Mustać : Mika S. Naor : Amira Nassieb : Alvydas Navickas : Tarek Okasha : Milena Pandova : Anca-Livia Panfil : Liliya Panteleeva : Ion Papava : Alexey Pavlichenko : Bojana Pejuskovic : Mariana Pinto da Costa : Mikhail Popkov : Dina Popovic : Nor Jannah Nasution Raduan : Francisca Vargas Ramírez : Elmars Rancans : Nurul Azreen Hashim : Federico Rebok : Anna Rewekant : Elena Ninoska Reyes Flores : María Teresa Rivera-Encinas : Pilar Saiz : Manuel Sánchez de Carmona : David Saucedo Martínez : Jo Anne Saw : Görkem Saygili : Patricia Schneiderreit : Bhumika Shah : Tomohiro Shirasaka : Ketevan Silagadze : Satti Sitanggang : Oleg Skugarevsky : Anna Spikina : Sridevi Sira Mahalingappa : Maria Stoyanova : Anna Szczegielniak : Simona Claudia Tamasan : Giuseppe Tavormina : Maurilio Giuseppe Maria Tavormina : Mauricio Tohen : Eva Maria Tsapakis : Dina Tukhvatullina : Irfan Ullah : Ratnaraj Vaidya : Johann M. Vega-Dienstmaier : Jelena Vrublevska : Olivera Vukovic : Olga Vysotska : Natalia Widiasih : Anna Yashikhina : Daria Smirnova :

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgment

None

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at [doi:10.1016/j.psychres.2025.116459](https://doi.org/10.1016/j.psychres.2025.116459).

References

1993. Health care reform for Americans with severe mental illnesses: report of the National Advisory Mental Health Council. *Am. J. Psychiatry* 150 (10), 1447–1465.
- Addington, D., Addington, J., Patten, S., Remington, G., Moamai, J., Labelle, A., Beaulclair, L., 2002. Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia. *J. Clin. Psychopharmacol.* 22 (1), 20–25.
- Agle, J., Xiao, Y., 2021. Misinformation about COVID-19: evidence for differential latent profiles and a strong association with trust in science. *BMC. Public Health* 21 (1), 89.

- Angermeyer, M.C., Matschinger, H., Schomerus, G., 2013. Attitudes towards psychiatric treatment and people with mental illness: changes over two decades. *Br. J. Psychiatry* 203 (2), 146–151.
- Bagewadi, V.I., Kumar, C.N., Thirthalli, J., Rao, G.N., Suresha, K.K., Gangadhar, B.N., 2016. Standardized mortality ratio in patients with Schizophrenia - findings from Thirthahalli: a rural South Indian community. *Indian J. Psychol. Med.* 38 (3), 202–206.
- Bartova, L., Dold, M., Kautzky, A., Rabl, U., Souery, D., Mendlewicz, J., Porcelli, S., Serretti, A., Zohar, J., Montgomery, S., Kasper, S., 2016. PS75. Psychopharmacoepidemiology of major depressive disorder in european tertiary psychiatric Treatment centers. *Int. J. Neuropsychopharmacol.* 19 (Suppl.1), 25–26.
- Bebbington, P., Ramana, R., 1995. The epidemiology of bipolar affective disorder. *Soc. Psychiatry Psychiatr. Epidemiol.* 30 (6), 279–292.
- Bernardo, M., Rico-Villademoros, F., García-Rizo, C., Rojo, R., Gomez-Huelgas, R., 2021. Real-world data on the adverse metabolic effects of second-generation antipsychotics and their potential determinants in adult patients: a systematic review of population-based studies. *Adv. Ther.* 38 (5), 2491–2512.
- Bijjal, S., Ganesh, S., Rawat, V.S., Agarwal, V., Shanivaram Reddy, K., Renuka Devi, N.R., Kumar, C.N., Christopher, R., Thirthalli, J., 2018. Six months' course and outcome of metabolic abnormalities in a cohort of patients with schizophrenia in rural India. *Schizophr. Res.* 201, 415–416.
- Bitter, I., Czobor, P., Borsi, A., Feher, L., Nagy, B.Z., Bacska, M., Rakonczai, P., Hegyi, R., Nemeth, T., Varga, P., Gimesi-Orszagh, J., Fadgyas-Freyler, P., Sermon, J., Takacs, P., 2017. Mortality and the relationship of somatic comorbidities to mortality in schizophrenia. A nationwide matched-cohort study. *Eur. Psychiatry* 45, 97–103.
- Borges, G., Angst, J., Nock, M.K., Ruscio, A.M., Walters, E.E., Kessler, R.C., 2006. A risk index for 12-month suicide attempts in the national comorbidity survey replication (NCS-R). *Psychol. Med.* 36 (12), 1747–1757.
- Borges, G., Nock, M.K., Haro Abad, J.M., Hwang, I., Sampson, N.A., Alonso, J., Andrade, L.H., Angermeyer, M.C., Beautrais, A., Bromet, E., Bruffaerts, R., de Girolamo, G., Florescu, S., Gureje, O., Hu, C., Karam, E.G., Kovess-Masfety, V., Lee, S., Levinson, D., Medina-Mora, M.E., Ormel, J., Posada-Villa, J., Sagar, R., Tomov, T., Uda, H., Williams, D.R., Kessler, R.C., 2010. Twelve-month prevalence of and risk factors for suicide attempts in the world health organization world mental health surveys. *J. Clin. Psychiatry* 71 (12), 1617–1628.
- Bourdon, K.H., Rae, D.S., Locke, B.Z., Narrow, W.E., Regier, D.A., 1992. Estimating the prevalence of mental disorders in U.S. adults from the Epidemiologic Catchment Area Survey. *Public Health Rep.* 107 (6), 663–668.
- Buchanan, R.W., Kreyenbuhl, J., Kelly, D.L., Noel, J.M., Boggs, D.L., Fischer, B.A., Himmelhoch, S., Fang, B., Peterson, E., Aquino, P.R., Keller, W., Schizophrenia Patient Outcomes Research, T., 2010. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. *Schizophr. Bull.* 36 (1), 71–93.
- Campbell, I., 2007. Chi-squared and Fisher-Irwin tests of two-by-two tables with small sample recommendations. *Stat. Med.* 26 (19), 3661–3675.
- Carli, M., Kolachalam, S., Longoni, B., Pintauro, A., Baldini, M., Aringhieri, S., Fasciani, I., Annibale, P., Maggio, R., Scarselli, M., 2021. Atypical antipsychotics and metabolic syndrome: from molecular mechanisms to clinical differences. *Pharmaceuticals*. (Basel) 14 (3).
- Carvalho, A.F., McIntyre, R.S., Dimelis, D., Gonda, X., Berk, M., Nunes-Neto, P.R., Cha, D. S., Hyphantis, T.N., Angst, J., Fountoulakis, K.N., 2014a. Predominant polarity as a course specifier for bipolar disorder: a systematic review. *J. Affect. Disord.* 163, 56–64.
- Carvalho, A.F., Quevedo, J., McIntyre, R.S., Soeiro-de-Souza, M.G., Fountoulakis, K.N., Berk, M., Hyphantis, T.N., Vieta, E., 2014b. Treatment implications of predominant polarity and the polarity index: a comprehensive review. *Int. J. Neuropsychopharmacol.* 18 (2).
- Chakos, M.H., Glick, I.D., Miller, A.L., Hamner, M.B., Miller, D.D., Patel, J.K., Tapp, A., Keefe, R.S., Rosenheck, R.A., 2006. Special section on CATIE baseline data: baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. *Psychiatric Serv.* 57 (8), 1094–1101.
- Chen, L., Selvendra, A., Stewart, A., Castle, D., 2018. Risk factors in early and late onset schizophrenia. *Compr. Psychiatry* 80, 155–162.
- Cipriano, A., Cella, S., Cotrufo, P., 2017. Nonsuicidal self-injury: a systematic review. *Front. Psychol.* 8, 1946.
- Correll, C.U., 2007. Balancing efficacy and safety in treatment with antipsychotics. *CNS. Spectr.* 12 (10 Suppl 17), 12–20, 35.
- Correll, C.U., Galling, B., Pawar, A., Krivko, A., Bonetto, C., Ruggeri, M., Craig, T.J., Nordentoft, M., Srihari, V.H., Guloksuz, S., Hui, C.L.M., Chen, E.Y.H., Valencia, M., Juarez, F., Robinson, D.G., Schooler, N.R., Brunette, M.F., Mueser, K.T., Rosenheck, R.A., Marcy, P., Addington, J., Estroff, S.E., Robinson, J., Penn, D., Severe, J.B., Kane, J.M., 2018. Comparison of early intervention services vs treatment as usual for early-phase psychosis: a systematic review, meta-analysis, and meta-regression. *JAMA Psychiatry* 75 (6), 555–565.
- Crump, C., Winkleby, M.A., Sundquist, K., Sundquist, J., 2013. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. *Am. J. Psychiatry* 170 (3), 324–333.
- Daniel, D.G., Randolph, C., Jaskiw, G., Handel, S., Williams, T., Abi-Dargham, A., Shoaf, S., Egan, M., Elkashef, A., Liboff, S., 1994. Coadministration of fluvoxamine increases serum: concentrations of haloperidol. *LWW* 340–343.
- Dell'Osso, B., Cafaro, R., Ketter, T.A., 2021. Has bipolar disorder become a predominantly female gender related condition? Analysis of recently published large sample studies. *Int. J. Bipolar. Disord.* 9 (1), 3.
- Dimellis, D., Fountoulakis, K.N., 2015. Pharmacoeconomics of Bipolar disorder: a review.

- Dragioti, E., Solmi, M., Favaro, A., Fusar-Poli, P., Dazzan, P., Thompson, T., Stubbs, B., Firth, J., Fornaro, M., Tsartalis, D., Carvalho, A.F., Vieta, E., McGuire, P., Young, A. H., Shin, J.I., Correll, C.U., Evangelou, E., 2019. Association of antidepressant use with adverse health outcomes: a systematic umbrella review. *JAMA Psychiatry* 76 (12), 1241–1255.
- Eaton, W.W., 1991. Update on the epidemiology of schizophrenia. *Epidemiol. Rev.* 13, 320–328.
- Eranti, S.V., MacCabe, J.H., Bundy, H., Murray, R.M., 2013. Gender difference in age at onset of schizophrenia: a meta-analysis. *Psychol. Med.* 43 (1), 155–167.
- Fagerlund, B., Pantelis, C., Jepsen, J.R.M., Raghava, J.M., Rostup, E., Thomas, M.B., Nielsen, M.O., Bojesen, K., Jensen, K.G., Stentebjerg-Decara, M., Klauber, D.G., Ruda, D., Ebdrup, B.H., Jessen, K., Sigvard, A., Tangmose, K., Jeppesen, P., Correll, C.U., Fink-Jensen, A., Pagsberg, A.K., Glenthoj, B.Y., 2021. Differential effects of age at illness onset on verbal memory functions in antipsychotic-naïve schizophrenia patients aged 12–43 years. *Psychol. Med.* 51 (9), 1570–1580.
- Fairweather-Schmidt, A.K., Anstey, K.J., 2012. Prevalence of suicidal behaviours in two Australian general population surveys: methodological considerations when comparing across studies. *Soc. Psychiatry Psychiatr. Epidemiol.* 47 (4), 515–522.
- Fenton, W.S., Chavez, M.R., 2006. Medication-induced weight gain and dyslipidemia in patients with schizophrenia. *Am. J. Psychiatry* 163 (10), 1697–1704 quiz 1858–1699.
- Fond, G., Tinland, A., Boucekine, M., Girard, V., Loubiere, S., Auquier, P., Boyer, L., French Housing First Study, G., 2019. Prescription of potentially inappropriate psychotropic drugs in homeless people with schizophrenia and bipolar disorders. Results from the French Housing First (FHF) program. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 89, 84–89.
- Fountoulakis, K.N., 2015. Classification and epidemiology. In: Fountoulakis, K.N. (Ed.), *Bipolar Disorder*. Springer Berlin Heidelberg, Berlin, Heidelberg, pp. 341–360.
- Fountoulakis, K.N., Apostolidou, M.K., Atsiova, M.B., Filippidou, A.K., Florou, A.K., Gousiou, D.S., Katsara, A.R., Mantzari, S.N., Padouva-Markoulaki, M., Papatriantafyllou, E.I., Sacharidi, P.I., Tonia, A.I., Tsagalidou, E.G., Zymara, V.P., Prezerakos, P.E., Koupidis, S.A., Fountoulakis, N.K., Chrousos, G.P., 2021a. Self-reported changes in anxiety, depression and suicidality during the COVID-19 lockdown in Greece. *J. Affect. Disord.* 279, 624–629.
- Fountoulakis, K.N., Apostolidou, M.K., Atsiova, M.B., Filippidou, A.K., Florou, A.K., Gousiou, D.S., Katsara, A.R., Mantzari, S.N., Padouva-Markoulaki, M., Papatriantafyllou, E.I., Sacharidi, P.I., Tonia, A.I., Tsagalidou, E.G., Zymara, V.P., Prezerakos, P.E., Koupidis, S.A., Fountoulakis, N.K., Konsta, A., Tsapakis, E.M., Theodorakis, P.N., Mossialos, E., 2022a. Mental health and conspirasism in health care professionals during the spring 2020 COVID-19 lockdown in Greece. *Acta Neuropsychiatr.* 34 (3), 132–147.
- Fountoulakis, K.N., Dragioti, E., Theofilidis, A.T., Wiklund, T., Atmatzidis, X., Nimatoudis, I., Thys, E., Wampers, M., Hranov, L., Hristova, T., Aptalidis, D., Milev, R., Iftene, F., Spaniel, F., Knytl, P., Furstova, P., From, T., Karlsson, H., Walta, M., Salokangas, R.K.R., Azorin, J.M., Bouniard, J., Montant, J., Juckel, G., Haussleiter, I.S., Douzenis, A., Michopoulos, I., Ferentinos, P., Smyrnis, N., Mantoukakis, L., Nemes, Z., Gonda, X., Vajda, D., Juhasz, A., Shrivastava, A., Waddington, J., Pompili, M., Comparelli, A., Corigliano, V., Rancans, E., Navickas, A., Hilbig, J., Bukelskis, L., Injac Stevovic, L., Vodopiec, S., Esan, O., Oladele, O., Osunbote, C., Rybakowski, J., Wojciak, P., Domowicz, K., Figueira, M.L., Linhares, L., Crawford, J., Panfil, A.L., Smirnova, D., Izmailova, O., Lecic-Tosevski, D., Temmingh, H., Howells, F., Bobes, J., Garcia-Portilla, M.P., Garcia-Alvarez, L., Erzlin, G., Karadag, H., De Sousa, A., Bendre, A., Hoschl, C., Bredicean, C., Papava, I., Vukovic, O., Pejuskovic, B., Russell, V., Athanasiadis, L., Konsta, A., Stein, D., Berk, M., Dean, O., Tandon, R., Kasper, S., De Hert, M., 2019. Staging of schizophrenia with the use of PANSS: an international Multi-center study. *Int. J. Neuropsychopharmacol.* 22 (11), 681–697.
- Fountoulakis, K.N., Dragioti, E., Theofilidis, A.T., Wiklund, T., Atmatzidis, X., Nimatoudis, I., Thys, E., Wampers, M., Hranov, L., Hristova, T., Aptalidis, D., Milev, R., Iftene, F., Spaniel, F., Knytl, P., Furstova, P., From, T., Karlsson, H., Walta, M., Salokangas, R.K.R., Azorin, J.M., Bouniard, J., Montant, J., Juckel, G., Haussleiter, I.S., Douzenis, A., Michopoulos, I., Ferentinos, P., Smyrnis, N., Mantoukakis, L., Nemes, Z., Gonda, X., Vajda, D., Juhasz, A., Shrivastava, A., Waddington, J., Pompili, M., Comparelli, A., Corigliano, V., Rancans, E., Navickas, A., Hilbig, J., Bukelskis, L., Stevovic, L.I., Vodopiec, S., Esan, O., Oladele, O., Osunbote, C., Rybakowski, J.K., Wojciak, P., Domowicz, K., Figueira, M. L., Linhares, L., Crawford, J., Panfil, A.L., Smirnova, D., Izmailova, O., Lecic-Tosevski, D., Temmingh, H., Howells, F., Bobes, J., Garcia-Portilla, M.P., Garcia-Alvarez, L., Erzlin, G., Karadag, H., De Sousa, A., Bendre, A., Hoschl, C., Bredicean, C., Papava, I., Vukovic, O., Pejuskovic, B., Russell, V., Athanasiadis, L., Konsta, A., Stein, D., Berk, M., Dean, O., Tandon, R., Kasper, S., De Hert, M., 2021b. Modeling psychological function in patients with schizophrenia with the PANSS: an international multi-center study. *CNS. Spectr.* 26 (3), 290–298.
- Fountoulakis, K.N., Grammatikopoulos, I.A., Koupidis, S.A., Siamouli, M., Theodorakis, P.N., 2012. Health and the financial crisis in Greece. *Lancet* 379 (9820), 1001–1002 author reply 1002.
- Fountoulakis, K.N., Karakatsoulis, G., Abraham, S., Adorjan, K., Ahmed, H.U., Alarcon, R. D., Arai, K., Auwal, S.S., Berk, M., Bjedov, S., Bobes, J., Bobes-Bascaran, T., Bourgin-Duchesnay, J., Bredicean, C.A., Bukelskis, L., Burkadze, A., Abud, I.I.C., Castilla-Puentes, R., Cetkovich, M., Colon-Rivera, H., Corral, R., Cortez-Vergara, C., Crepin, P., De Berardis, D., Zamora Delgado, S., De Lucena, D., De Sousa, A., Stefano, R.D., Dodd, S., Elek, L.P., Elissa, A., Erdelyi-Hamza, B., Erzlin, G., Etchevers, M.J., Falkai, P., Farcas, A., Fedotov, I., Filatova, V., Fountoulakis, N.K., Frankova, I., Franza, F., Frias, P., Galako, T., Garay, C.J., Garcia-Alvarez, L., Garcia-Portilla, M.P., Gonda, X., Gondek, T.M., Gonzalez, D.M., Gould, H., Grandinetti, P., Grau, A., Groudeva, V., Hagin, M., Harada, T., Hasan, M.T., Hashim, N.A., Hilbig, J., Hossain, S., Iakimova, R., Ibrahim, M., Iftene, F., Ignatenko, Y., Irarrazaval, M., Ismail, Z., Ismayilova, J., Jacobs, A., Jakovljevic, M., Jaksic, N., Javed, A., Kafali, H. Y., Karia, S., Kazakova, O., Khalifa, D., Khaustova, O., Koh, S., Kopishinskaia, S., Kosenko, K., Koupidis, S.A., Kovacs, I., Kulig, B., Lalljee, A., Liewig, J., Majid, A., Malashonkova, E., Malik, K., Malik, N.I., Mammadzada, G., Mandalia, B., Marazziti, D., Marcinko, D., Martinez, S., Matiekus, E., Mejia, G., Memon, R.S., Martinez, X.E.M., Mickeviciute, D., Milev, R., Mohammed, M., Molina-Lopez, A., Morozov, P., Muhammad, N.S., Mustac, F., Naor, M.S., Nassieb, A., Navickas, A., Okasha, T., Pandova, M., Panfil, A.L., Panteleeva, L., Papava, I., Patsali, M.E., Pavlichenko, A., Pejuskovic, B., Da Costa, M.P., Popkov, M., Popovic, D., Raduan, N. J.N., Ramirez, F.V., Rancans, E., Razali, S., Rebok, F., Rewekant, A., Flores, E.N.R., Rivera-Encinas, M.T., Saiz, P., de Carmona, M.S., Martinez, D.S., Saw, J.A., Saygili, G., Schneiderreit, P., Shah, B., Shirasaka, T., Silagadze, K., Sitanggang, S., Skugarevsky, O., Spikina, A., Mahalingappa, S.S., Stoyanova, M., Szczegielniak, A., Tamasan, S.C., Tavormina, G., Tavormina, M.G.M., Theodorakis, P.N., Tohen, M., Tsapakis, E.M., Tuhvatullina, D., Ullah, I., Vaidya, R., Vega-Dienstmaier, J.M., Vrublevska, J., Vukovic, O., Vysotska, O., Widiash, N., Yashikhina, A., Prezerakos, P.E., Smirnova, D., 2022b. Results of the COVID-19 mental health international for the general population (COMET-G) study. *Eur. Neuropsychopharmacol.* 54, 21–40.
- Fountoulakis, K.N., Karakatsoulis, G.N., Abraham, S., Adorjan, K., Ahmed, H.U., Alarcon, R.D., Arai, K., Auwal, S.S., Berk, M., Bjedov, S., Bobes, J., Bobes-Bascaran, T., Bourgin-Duchesnay, J., Bredicean, C.A., Bukelskis, L., Burkadze, A., Abud, I.I.C., Castilla-Puentes, R., Cetkovich, M., Colon-Rivera, H., Corral, R., Cortez-Vergara, C., Crepin, P., De Berardis, D., Delgado, S.Z., De Lucena, D., De Sousa, A., Stefano, R.D., Dodd, S., Elek, L.P., Elissa, A., Erdelyi-Hamza, B., Erzlin, G., Etchevers, M.J., Falkai, P., Farcas, A., Fedotov, I., Filatova, V., Fountoulakis, N.K., Frankova, I., Franza, F., Frias, P., Galako, T., Garay, C.J., Garcia-Alvarez, L., Garcia-Portilla, M.P., Gonda, X., Gondek, T.M., Gonzalez, D.M., Gould, H., Grandinetti, P., Grau, A., Groudeva, V., Hagin, M., Harada, T., Hasan, T.M., Hashim, N.A., Hilbig, J., Hossain, S., Iakimova, R., Ibrahim, M., Iftene, F., Ignatenko, Y., Irarrazaval, M., Ismail, Z., Ismayilova, J., Jacobs, A., Jakovljevic, M., Jaksic, N., Javed, A., Kafali, H. Y., Karia, S., Kazakova, O., Khalifa, D., Khaustova, O., Koh, S., Kopishinskaia, S., Kosenko, K., Koupidis, S.A., Kovacs, I., Kulig, B., Lalljee, A., Liewig, J., Majid, A., Malashonkova, E., Malik, K., Malik, N.I., Mammadzada, G., Mandalia, B., Marazziti, D., Marcinko, D., Martinez, S., Matiekus, E., Mejia, G., Memon, R.S., Martinez, X.E.M., Mickeviciute, D., Milev, R., Mohammed, M., Molina-Lopez, A., Morozov, P., Muhammad, N.S., Mustac, F., Naor, M.S., Nassieb, A., Navickas, A., Okasha, T., Pandova, M., Panfil, A.L., Panteleeva, L., Papava, I., Patsali, M.E., Pavlichenko, A., Pejuskovic, B., Da Costa, M.P., Popkov, M., Popovic, D., Raduan, N. J.N., Ramirez, F.V., Rancans, E., Razali, S., Rebok, F., Rewekant, A., Flores, E.N.R., Rivera-Encinas, M.T., Saiz, P., de Carmona, M.S., Martinez, D.S., Saw, J.A., Saygili, G., Schneiderreit, P., Shah, B., Shirasaka, T., Silagadze, K., Sitanggang, S., Skugarevsky, O., Spikina, A., Mahalingappa, S.S., Stoyanova, M., Szczegielniak, A., Tamasan, S.C., Tavormina, G., Tavormina, M.G.M., Theodorakis, P.N., Tohen, M., Tsapakis, E.M., Tuhvatullina, D., Ullah, I., Vaidya, R., Vega-Dienstmaier, J.M., Vrublevska, J., Vukovic, O., Vysotska, O., Widiash, N., Yashikhina, A., Prezerakos, P.E., Smirnova, D., 2022c. The effect of different degrees of lockdown and self-identified gender on anxiety, depression and suicidality during the COVID-19 pandemic: data from the international COMET-G study. *Psychiatry Res.* 315, 114702.
- Fountoulakis, K.N., Karakatsoulis, G.N., Abraham, S., Adorjan, K., Ahmed, H.U., Alarcon, R.D., Arai, K., Auwal, S.S., Berk, M., Bjedov, S., Bobes, J., Bobes-Bascaran, T., Bourgin-Duchesnay, J., Bredicean, C.A., Bukelskis, L., Burkadze, A., Cabrera II, A., Castilla-Puentes, R., Cetkovich, M., Colon-Rivera, H., Corral, R., Cortez-Vergara, C., Crepin, P., De Berardis, D., Zamora Delgado, S., Lucena, D., Sousa, A., Stefano, R.D., Dodd, S., Priyanka Elek, L., Elissa, A., Erdelyi-Hamza, B., Erzlin, G., Etchevers, M.J., Falkai, P., Farcas, A., Fedotov, I., Filatova, V., Fountoulakis, N.K., Frankova, I., Franza, F., Frias, P., Galako, T., Garay, C.J., Garcia-Alvarez, L., Garcia-Portilla, M.P., Gonda, X., Gondek, T.M., Morera Gonzalez, D., Gould, H., Grandinetti, P., Grau, A., Groudeva, V., Hagin, M., Harada, T., Hasan, T. M., Azreen Hashim, N., Hilbig, J., Hossain, S., Iakimova, R., Ibrahim, M., Iftene, F., Ignatenko, Y., Irarrazaval, M., Ismail, Z., Ismayilova, J., Jakobs, A., Jakovljevic, M., Jaksic, N., Javed, A., Kafali, H.Y., Karia, S., Kazakova, O., Khalifa, D., Khaustova, O., Koh, S., Kopishinskaia, S., Kosenko, K., Koupidis, S.A., Kovacs, I., Kulig, B., Lalljee, A., Liewig, J., Majid, A., Malashonkova, E., Malik, K., Malik, N.I., Mammadzada, G., Mandalia, B., Marazziti, D., Marcinko, D., Martinez, S., Matiekus, E., Mejia, G., Memon, R.S., Meza Martinez, X.E., Mickeviciute, D., Milev, R., Mohammed, M., Molina-Lopez, A., Morozov, P., Muhammad, N.S., Mustac, F., Naor, M.S., Nassieb, A., Navickas, A., Okasha, T., Pandova, M., Panfil, A. L., Panteleeva, L., Papava, I., Patsali, M.E., Pavlichenko, A., Pejuskovic, B., Pinto Da Costa, M., Popkov, M., Popovic, D., Raduan, N.J.N., Vargas Ramirez, F., Rancans, E., Razali, S., Rebok, F., Rewekant, A., Ninoska Reyes Flores, E., Rivera-Encinas, M.T., Saiz, P., Sanchez de Carmona, M., Saucedo Martinez, D., Saw, J.A., Saygili, G., Schneiderreit, P., Shah, B., Shirasaka, T., Silagadze, K., Sitanggang, S., Skugarevsky, O., Spikina, A., Mahalingappa, S.S., Stoyanova, M., Szczegielniak, A., Tamasan, S.C., Tavormina, G., Tavormina, M.G.M., Theodorakis, P.N., Tohen, M., Tsapakis, E.M., Tuhvatullina, D., Ullah, I., Vaidya, R., Vega-Dienstmaier, J.M., Vrublevska, J., Vukovic, O., Vysotska, O., Widiash, N., Yashikhina, A., Prezerakos, P.E., Smirnova, D., 2024. Somatic multimorbidity and disability in patients with psychiatric disorders in comparison to the general population: a quasi-epidemiological investigation in 54,826 subjects from 40 countries (COMET-G study). *CNS. Spectr.* 29 (2), 126–149.
- Fountoulakis, K.N., Tsapakis, E.M., 2024. Neither serotonin disorder is at the core of depression nor dopamine at the core of schizophrenia; still these are biologically based mental disorders. *Mol. Psychiatry* 29 (1), 198–199.

- Fusar-Poli, P., McGorry, P.D., Kane, J.M., 2017. Improving outcomes of first-episode psychosis: an overview. *World Psychiatry* 16 (3), 251–265.
- Galling, B., Vernon, J.A., Pagsberg, A.K., Wadhwa, A., Grudnikoff, E., Seidman, A.J., Tsou-Podosenin, M., Poyurovsky, M., Kane, J.M., Correll, C.U., 2018. Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia. *Acta Psychiatr. Scand.* 137 (3), 187–205.
- Goodwin, R.D., Dierker, L.C., Wu, M., Galea, S., Hoven, C.W., Weinberger, A.H., 2022. Trends in U.S. Depression prevalence from 2015 to 2020: the widening treatment gap. *Am. J. Prev. Med.* 63 (5), 726–733.
- Gramaglia, C., Gambaro, E., Bartolomei, G., Camera, P., Chiarelli-Serra, M., Lorenzini, L., Zeppegno, P., 2018. Increased risk of metabolic syndrome in antidepressants users: a mini review. *Front. Psychiatry* 9, 621.
- Greenfield, S.F., Brooks, A.J., Gordon, S.M., Green, C.A., Kropp, F., McHugh, R.K., Lincoln, M., Hien, D., Miele, G.M., 2007. Substance abuse treatment entry, retention, and outcome in women: a review of the literature. *Drug Alcohol Depend.* 86 (1), 1–21.
- Haram, A., Fosse, R., Jonsbu, E., Hole, T., 2019. Impact of psychotherapy in psychosis: a retrospective case control study. *Front. Psychiatry* 10, 204.
- Health Quality, O., 2018. Cognitive behavioural therapy for psychosis: a health technology assessment. *Ont. Health Technol. Assess. Ser.* 18 (5), 1–141.
- Himeloch, S., Slade, E., Kreyenbuhl, J., Medoff, D., Brown, C., Dixon, L., 2012. Antidepressant prescribing patterns among VA patients with schizophrenia. *Schizophr. Res.* 136 (1–3), 32–35.
- Hjorthøj, C., Sturup, A.E., McGrath, J.J., Nordentoft, M., 2017. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. *Lancet Psychiatry* 4 (4), 295–301.
- Ibrahim, F.A., Nirisha, L., Barikar, M., Kumar, C.N., Chand, P.K., Manjunatha, N., Math, S.B., Thirthalli, J., Manjappa, A.A., Parthasarathy, R., Reddy, S., Arora, S., 2021. Identification of psychiatric disorders by rural grass-root health workers: case series & implications for the National Mental Health Program of India. *Psychiatr. Q.* 92 (1), 389–395.
- Immonen, J., Jaaskelainen, E., Korpela, H., Miettinen, J., 2017. Age at onset and the outcomes of schizophrenia: a systematic review and meta-analysis. *Early. Interv. Psychiatry* 11 (6), 453–460.
- Jaaskelainen, E., Juola, P., Hirvonen, N., McGrath, J.J., Saha, S., Isohanni, M., Veijola, J., Miettinen, J., 2013. A systematic review and meta-analysis of recovery in schizophrenia. *Schizophr. Bull.* 39 (6), 1296–1306.
- Jones, P.B., 2013. Adult mental health disorders and their age at onset. *Br. J. Psychiatry* 154, s5–10.
- K, N.F., G, N.K., Abraham, S., Adorjan, K., Ahmed, H.U., Alarcon, R.D., Arai, K., Auwal, S. S., Bobes, J., Bobes-Bascaran, T., Bourgin-Duchesnay, J., Bredicean, C.A., Bukelskis, L., Burkadze, A., Cabrera II, A., Castilla-Puentes, R., Cetkovich, M., Colon-Rivera, H., Corral, R., Cortez-Vergara, C., Crepin, P., de Berardis, D., Zamora Delgado, S., de Lucena, D., de Sousa, A., di Stefano, R., Dodd, S., Elek, L.P., Elissa, A., Erdelyi-Hamza, B., Erzini, G., Etchevers, M.J., Falkai, P., Farcas, A., Fedotov, I., Filatova, V., Fountoulakis, N.K., Frankova, I., Franza, F., Frias, P., Galako, T., Garay, C.J., Garcia-Alvarez, L., Garcia-Portilla, P., Gonda, X., Gondek, T.M., Morera Gonzalez, D., Gould, H., Grandinetti, P., Grau, A., Groudeva, V., Hagin, M., Harada, T., Hasan, T.M., Azreen Hashim, N., Hilbig, J., Hossain, S., Iakimova, R., Ibrahim, M., Iftene, F., Ignatenko, Y., Irrarazaval, M., Ismail, Z., Ismayilova, J., Jacobs, A., Jakovljevic, M., Jaksic, N., Javed, A., Yilmaz Kafali, H., Karia, S., Kazakova, O., Khalifa, D., Khaustova, O., Koh, S., Kopishinskaya, S., Kosenko, K., Koupidis, S.A., Kovacs, I., Kulig, B., Laljee, A., Liewig, J., Majid, A., Malashonkova, E., Malik, K., Iqbal Malik, N., Mammadzada, G., Mandalia, B., Marazziti, D., Marcinko, D., Martinez, S., Matiekus, E., Mejia, G., Memon, R.S., Meza Martinez, X.E., Mickeviciute, D., Milev, R., Mohammed, M., Molina-Lopez, A., Morozov, P., Muhammad, N.S., Mustac, F., Naor, M.S., Nassieva, A., Navickas, A., Okasha, T., Pandova, M., Panfil, A.L., Panteleeva, L., Papava, I., Patsali, M.E., Pavlichenko, A., Pejuskovic, B., Pinto da Costa, M., Popkov, M., Popovic, D., Raduan, N.J.N., Vargas Ramirez, F., Rancans, E., Razali, S., Rebok, F., Rewekant, A., Reyes Flores, E.N., Rivera-Encinas, M.T., Saiz, P.A., Sanchez de Carmona, M., Saucedo Martinez, D., Saw, J.A., Saygili, G., Schneider, P., Shah, B., Shirasaka, T., Silagadze, K., Sitanggang, S., Skugarevsky, O., Spikina, A., Mahalingappa, S.S., Stoyanova, M., Szczegielniak, A., Tamasan, S.C., Tavormina, G., Tavormina, M.G.M., Theodorakis, P.N., Tohen, M., Tsapakis, E.M., Tukhvatullina, D., Ullah, I., Vaidya, R., Vega-Dienstmaier, J.M., Vrublevska, J., Vukovic, O., Vysotska, O., Widiastih, N., Yashikhina, A., Prezerakos, P.E., Berk, M., Levaj, S., Smirnova, D., 2023. Results of the COVID-19 mental health international for the health professionals (COMET-HP) study: depression, suicidal tendencies and conspiracism. *Soc. Psychiatry Psychiatr. Epidemiol.* 58 (9), 1387–1410.
- Kamenov, K., Twomey, C., Cabello, M., Prina, A.M., Ayuso-Mateos, J.L., 2017. The efficacy of psychotherapy, pharmacotherapy and their combination on functioning and quality of life in depression: a meta-analysis. *Psychol. Med.* 47 (3), 414–425.
- Kessing, L.V., Vradi, E., Andersen, P.K., 2016. Nationwide and population-based prescription patterns in bipolar disorder. *Bipolar. Disord.* 18 (2), 174–182.
- Kessler, R.C., Berglund, P.A., Bruce, M.L., Koch, J.R., Laska, E.M., Leaf, P.J., Manderscheid, R.W., Rosenheck, R.A., Walters, E.E., Wang, P.S., 2001. The prevalence and correlates of untreated serious mental illness. *Health Serv. Res.* 36 (6 Pt 1), 987–1007.
- Kessler, R.C., Borges, G., Walters, E.E., 1999. Prevalence of and risk factors for lifetime suicide attempts in the National Comorbidity Survey. *Arch. Gen. Psychiatry* 56 (7), 617–626.
- Kohler, S., van der Werf, M., Hart, B., Morrison, G., McCreddie, R., Kirkpatrick, B., Verkaik, M., Krabbendam, L., Verhey, F., van Os, J., Allardyce, J., 2009. Evidence that better outcome of psychosis in women is reversed with increasing age of onset: a population-based 5-year follow-up study. *Schizophr. Res.* 113 (2–3), 226–232.
- Kumar, C.N., Suresha, K.K., Thirthalli, J., Arunachala, U., Gangadhar, B.N., 2015a. Caregiver burden is associated with disability in schizophrenia: results of a study from a rural setting of south India. *Int. J. Soc. Psychiatry* 61 (2), 157–163.
- Kumar, C.N., Thirthalli, J., Suresha, K.K., Arunachala, U., Gangadhar, B.N., 2013. Metabolic syndrome among schizophrenia patients: study from a rural community of south India. *Asian J. Psychiatr.* 6 (6), 532–536.
- Kumar, C.N., Thirthalli, J., Suresha, K.K., Arunachala, U., Gangadhar, B.N., 2015b. Alcohol use disorders in patients with schizophrenia: comparative study with general population controls. *Addict. Behav.* 45, 22–25.
- Kumar, C.N., Thirthalli, J., Suresha, K.K., Lebowitz, B.D., Severe, J., Hsiao, J.K., Clinical Antipsychotic Trials of Intervention Effectiveness, I., 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N. Engl. J. Med.* 353 (12), 1209–1223.
- Lim, G.Y., Tam, W.W., Lu, Y., Ho, C.S., Zhang, M.W., Ho, R.C., 2018. Prevalence of depression in the community from 30 countries between 1994 and 2014. *Sci. Rep.* 8 (1), 2861.
- Liu, X., Huang, Y., Liu, Y., 2018. Prevalence, distribution, and associated factors of suicide attempts in young adolescents: school-based data from 40 low-income and middle-income countries. *PLoS One* 13 (12), e0207823.
- Lucena, N.L., Rossi, T.A., Azevedo, L.M.G., Pereira, M., 2022. Self-injury prevalence in adolescents: a global systematic review and meta-analysis. *Child Youth. Serv. Rev.* 142, 106634.
- Lyall, L.M., Penades, N., Smith, D.J., 2019. Changes in prescribing for bipolar disorder between 2009 and 2016: national-level data linkage study in Scotland. *Br. J. Psychiatry* 215 (1), 415–421.
- Manjunatha, N., Kumar, C.N., Thirthalli, J., Suresha, K.K., Harisha, D.M., Arunachala, U., 2019. Mortality in schizophrenia: a study of verbal autopsy from cohorts of two rural communities of South India. *Indian J. Psychiatry* 61 (3), 238–243.
- McGrath, J., Saha, S., Chant, D., Welham, J., 2008. Schizophrenia: a concise overview of incidence, prevalence, and mortality. *Epidemiol. Rev.* 30, 67–76.
- Medici, C.R., Videbech, P., Gustafsson, L.N., Munk-Jorgensen, P., 2015. Mortality and secular trend in the incidence of bipolar disorder. *J. Affect. Disord.* 183, 39–44.
- Merikangas, K.R., Jin, R., He, J.P., Kessler, R.C., Lee, S., Sampson, N.A., Viana, M.C., Andrade, L.H., Hu, C., Karam, E.G., Ladea, M., Medina-Mora, M.E., Ono, Y., Posada-Villa, J., Sagar, R., Wells, J.E., Zarkov, Z., 2011. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. *Arch. Gen. Psychiatry* 68 (3), 241–251.
- Mojtabai, R., Olsson, M., 2010. National trends in psychotropic medication polypharmacy in office-based psychiatry. *Arch. Gen. Psychiatry* 67 (1), 26–36.
- Mulholland, C., Lynch, G., King, D.J., Cooper, S.J., 2003. A double-blind, placebo-controlled trial of sertraline for depressive symptoms in patients with stable, chronic schizophrenia. *J. Psychopharmacol.* 17 (1), 107–112.
- Munder, T., Fluckiger, C., Leichsenring, F., Abbass, A.A., Hilsenroth, M.J., Luyten, P., Rabung, S., Steinert, C., Wampold, B.E., 2019. Is psychotherapy effective? A re-analysis of treatments for depression. *Epidemiol. Psychiatr. Sci.* 28 (3), 268–274.
- Myles, N., Newall, H., Compton, M.T., Curtis, J., Nielsen, O., Large, M., 2012. The age at onset of psychosis and tobacco use: a systematic meta-analysis. *Soc. Psychiatry Psychiatr. Epidemiol.* 47 (8), 1243–1250.
- Narrow, W.E., Regier, D.A., Norquist, G., Rae, D.S., Kennedy, C., Arons, B., 2000. Mental health service use by Americans with severe mental illnesses. *Soc. Psychiatry Psychiatr. Epidemiol.* 35 (4), 147–155.
- Ng, V.W.S., Man, K.K.C., Gao, L., Chan, E.W., Lee, E.H.M., Hayes, J.F., Wong, I.C.K., 2021. Bipolar disorder prevalence and psychotropic medication utilisation in Hong Kong and the United Kingdom. *Pharmacoeconomics* 30 (11), 1588–1600.
- Nivoli, A.M., Pacchiarotti, I., Rosa, A.R., Popovic, D., Murru, A., Valenti, M., Bonnin, C. M., Grande, I., Sanchez-Moreno, J., Vieta, E., Colom, F., 2011. Gender differences in a cohort study of 604 bipolar patients: the role of predominant polarity. *J. Affect. Disord.* 133 (3), 443–449.
- Nock, M.K., Borges, G., Bromet, E.J., Alonso, J., Angermeyer, M., Beautrais, A., Bruffaerts, R., Chiu, W.T., de Girolamo, G., Gluzman, S., de Graaf, R., Gureje, O., Haro, J.M., Huang, Y., Karam, E., Kessler, R.C., Lepine, J.P., Levinson, D., Medina-Mora, M.E., Ono, Y., Posada-Villa, J., Williams, D., 2008. Cross-national prevalence and risk factors for suicidal ideation, plans and attempts. *Br. J. Psychiatry* 192 (2), 98–105.
- Ochoa, S., Usall, J., Cobo, J., Labad, X., Kulkarni, J., 2012. Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review. *Schizophr. Res. Treatment* 2012, 916198.
- Okrent, E., Reif, S., Horgan, C.M., 2023. Development of an addiction recovery patient-reported outcome measure: response to addiction recovery (R2AR). *Subst. Abuse Treat. Prev. Policy.* 18 (1), 52.
- Olsson, M., Gerhard, T., Huang, C., Crystal, S., Stroup, T.S., 2015. Premature mortality among adults with schizophrenia in the United States. *JAMA Psychiatry* 72 (12), 1172–1181.
- Olsson, M., Marcus, S.C., Doshi, J.A., 2010. Continuity of care after inpatient discharge of patients with schizophrenia in the Medicaid program: a retrospective longitudinal cohort analysis. *J. Clin. Psychiatry* 71 (7), 831–838.

- Olie, J.P., Elomari, F., Spadone, C., Lepine, J.P., 2002. [Antidepressants consumption in the global population in France]. *Encephale* 28 (5 Pt 1), 411–417.
- Patsali, M.E., Mousa, D.V., Papadopoulou, E.V.K., Papadopoulou, K.K.K., Kaparounaki, C.K., Diakogiannis, I., Fountoulakis, K.N., 2020. University students' changes in mental health status and determinants of behavior during the COVID-19 lockdown in Greece. *Psychiatry Res.* 292, 113298.
- Penninx, B., Lange, S.M.M., 2018. Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications. *Dialogues. Clin. Neurosci.* 20 (1), 63–73.
- Pillinger, T., McCutcheon, R.A., Vano, L., Mizuno, Y., Arumham, A., Hindley, G., Beck, K., Natesan, S., Efthimiou, O., Cipriani, A., Howes, O.D., 2020. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. *Lancet Psychiatry* 7 (1), 64–77.
- Pini, S., de Queiroz, V., Pagnin, D., Pezawas, L., Angst, J., Cassano, G.B., Wittchen, H.U., 2005. Prevalence and burden of bipolar disorders in European countries. *Eur. Neuropsychopharmacol.* 15 (4), 425–434.
- Plana-Ripoll, O., Momen, N.C., McGrath, J.J., Wimberley, T., Brikell, I., Schendel, D., Thygesen, M., Weyer, N., Pedersen, C.B., Mors, O., Mortensen, P.B., Dalsgaard, S., 2022. Temporal changes in sex- and age-specific incidence profiles of mental disorders—A nationwide study from 1970 to 2016. *Acta Psychiatr. Scand.* 145 (6), 604–614.
- Rasgon, N., Bauer, M., Grof, P., Gyulai, L., Elman, S., Glenn, T., Whybrow, P.C., 2005. Sex-specific self-reported mood changes by patients with bipolar disorder. *J. Psychiatr. Res.* 39 (1), 77–83.
- Rawat, V.S., Ganesh, S., Bijjal, S., Shanivaram Reddy, K., Agarwal, V., Devi, R., Kumar, C. N., Christopher, R., Thirthalli, J., 2018. Prevalence and predictors of metabolic syndrome in patients with schizophrenia and healthy controls: a study in rural South Indian population. *Schizophr. Res.* 192, 102–107.
- Reddy, K.S., Thirthalli, J., Kumar, C.N., Reddy, N.K., Bijjal, S., Renuka Devi, N.R., Rawat, V.S., 2017. Treatment discontinuation in schizophrenia: a qualitative exploration from a rural South Indian community. *J. Neurosci. Rural. Pract.* 8 (2), 254–260.
- Rhee, T.G., Olsson, M., Nierenberg, A.A., Wilkinson, S.T., 2020. 20-Year trends in the pharmacologic treatment of bipolar disorder by psychiatrists in outpatient care settings. *Am. J. Psychiatry* 177 (8), 706–715.
- Richardson, J.T., 2011. The analysis of 2x2 contingency tables—yet again. *Stat. Med.* 30 (8), 890 author reply 891–892.
- Robinson, D.G., 2016. Early Mortality Among People With Schizophrenia. *Am. Psychiatric Assoc.*, pp. 554–555.
- Saha, S., Chant, D., McGrath, J., 2007. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? *Arch. Gen. Psychiatry* 64 (10), 1123–1131.
- Schmidtke, A., Bille-Brahe, U., DeLeo, D., Kerkhof, A., Bjerke, T., Crepet, P., Haring, C., Hawton, K., Lonnqvist, J., Michel, K., Pommereau, X., Querejeta, I., Phillippe, I., Salander-Renberg, E., Temesvary, B., Wasserman, D., Fricke, S., Weinacker, B., Sampaio-Faria, J.G., 1996. Attempted suicide in Europe: rates, trends and sociodemographic characteristics of suicide attempters during the period 1989–1992. Results of the WHO/EURO Multicentre Study on parasuicide. *Acta Psychiatr. Scand.* 93 (5), 327–338.
- Schomerus, G., Schwahn, C., Holzinger, A., Corrigan, P.W., Grabe, H.J., Carta, M.G., Angermeyer, M.C., 2012. Evolution of public attitudes about mental illness: a systematic review and meta-analysis. *Acta Psychiatr. Scand.* 125 (6), 440–452.
- Scott, J., Etain, B., Azorin, J.M., Bellivier, F., 2018. Secular trends in the age at onset of bipolar I disorder - support for birth cohort effects from interational, multi-centre clinical observational studies. *Eur. Psychiatry* 52, 61–67.
- Sepehry, A.A., Potvin, S., Elie, R., Stip, E., 2007. Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. *J. Clin. Psychiatry* 68 (4), 604–610.
- Silver, H., 2003. Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. *Int. Clin. Psychopharmacol.* 18 (6), 305–313.
- Singh, S.P., Singh, V., Kar, N., Chan, K., 2010. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. *Br. J. Psychiatry* 197 (3), 174–179.
- Solmi, M., Radua, J., Olivola, M., Croce, E., Soardo, L., Salazar de Pablo, G., Il Shin, J., Kirkbride, J.B., Jones, P., Kim, J.H., Kim, J.Y., Carvalho, A.F., Seeman, M.V., Correll, C.U., Fusar-Poli, P., 2022. Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies. *Mol. Psychiatry* 27 (1), 281–295.
- Suppes, T., McElroy, S.L., Hirschfeld, R., 2007. Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder: a survey of 500 US psychiatrists. *Psychopharmacol. Bull.* 40 (2), 22–37 quiz 38–40.
- Suresh, K.K., Kumar, C.N., Thirthalli, J., Bijjal, S., Venkatesh, B.K., Arunachala, U., Kishorekumar, K.V., Subbakrishna, D.K., Gangadhar, B.N., 2012. Work functioning of schizophrenia patients in a rural south Indian community: status at 4-year follow-up. *Soc. Psychiatry Psychiatr. Epidemiol.* 47 (11), 1865–1871.
- Taipale, H., Mittendorfer-Rutz, E., Alexanderson, K., Majak, M., Mehtala, J., Hoti, F., Jedenius, E., Enksson, D., Leval, A., Sermon, J., Tanskanen, A., Tiihonen, J., 2018. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. *Schizophr. Res.* 197, 274–280.
- Tiihonen, J., Haukka, J., Taylor, M., Haddad, P.M., Patel, M.X., Korhonen, P., 2011. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. *Am. J. Psychiatry* 168 (6), 603–609.
- Tiihonen, J., Lonnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., Haukka, J., 2009. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). *Lancet* 374 (9690), 620–627.
- Tiihonen, J., Mittendorfer-Rutz, E., Torniainen, M., Alexanderson, K., Tanskanen, A., 2016. Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study. *Am. J. Psychiatry* 173 (6), 600–606.
- Tiihonen, J., Wahlbeck, K., Lonnqvist, J., Klaukka, T., Ioannidis, J.P., Volavka, J., Haukka, J., 2006. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. *BMJ* 333 (7561), 224.
- Torniainen, M., Mittendorfer-Rutz, E., Tanskanen, A., Bjorkenstam, C., Suvisaari, J., Alexanderson, K., Tiihonen, J., 2015. Antipsychotic treatment and mortality in schizophrenia. *Schizophr. Bull.* 41 (3), 656–663.
- Turner, D.T., van der Gaag, M., Karyotaki, E., Cuijpers, P., 2014. Psychological interventions for psychosis: a meta-analysis of comparative outcome studies. *Am. J. Psychiatry* 171 (5), 523–538.
- Udupi, S.A., Kumar, C.N., Suresh, K.K., Arunachala, U., Thirthalli, J., 2018. Prevalence & correlates of areca use among rural south Indian schizophrenia patients: a comparative study with general population. *Asian J. Psychiatry* 38, 60–64.
- Van Meter, A.R., Knowles, E.A., Mintz, E.H., 2023. Systematic review and meta-analysis: international prevalence of suicidal ideation and attempt in youth. *J. Am. Acad. Child Adolesc. Psychiatry* 62 (9), 973–986.
- Vanasse, A., Blais, L., Courteau, J., Cohen, A.A., Roberge, P., Larouche, A., Grignon, S., Fleury, M.J., Lesage, A., Demers, M.F., Roy, M.A., Carrier, J.D., Delorme, A., 2016. Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real-world observational study. *Acta Psychiatr. Scand.* 134 (5), 374–384.
- Vanelli, M., Burstein, P., Cramer, J., 2001. Refill patterns of atypical and conventional antipsychotic medications at a national retail pharmacy chain. *Psychiatr. Serv.* 52 (9), 1248–1250.
- Walker, E.R., McGee, R.E., Druss, B.G., 2015. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. *JAMA Psychiatry* 72 (4), 334–341.
- Whitehead, C., Moss, S., Cardno, A., Lewis, G., Furtado, V.A., Group, C.S., 1996. Antidepressants for people with both schizophrenia and depression. *Cochrane Database Syst. Rev.* 2013 (4).
- Wittchen, H.U., Jacobi, F., 2005. Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies. *Eur. Neuropsychopharmacol.* 15 (4), 357–376.
- Xu, L., Guo, Y., Cao, Q., Li, X., Mei, T., Ma, Z., Tang, X., Ji, Z., Yang, L., Liu, J., 2020. Predictors of outcome in early onset schizophrenia: a 10-year follow-up study. *BMC Psychiatry* 20 (1), 67.
- Zhang, M., Chen, J., Yin, Z., Wang, L., Peng, L., 2021. The association between depression and metabolic syndrome and its components: a bidirectional two-sample mendelian randomization study. *Transl. Psychiatry* 11 (1), 633.